Podcasts about BMS

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Hour 4 of June 8, 2026 Jacob Townsend talks with Deb Williams, of Autoweek.com, about Denny Hamlin's second straight victory at Michigan, his 63rd career win, Carson Hocevar, Chase Elliott/Christopher Bell crash, Ned Jarrett passing, and more. Then, Jacob is joined by Brandon Cross, of Bristol Motor Speedway, to promote Super Grip NHRA Thunder Valley Nationals this weekend at BMS. Also, Jacob talks about Denny Hamlin's victory and Carson Hocevar's aggressiveness. See omnystudio.com/listener for privacy information.

Jacob Townsend is joined by Brandon Cross, of Bristol Motor Speedway, to promote Super Grip NHRA Thunder Valley Nationals this weekend at BMS.See omnystudio.com/listener for privacy information.

Adam Haman returns to help Bob offer praise and criticism for Jeremy Kauffman's recent speech at the Libertarian Party's national convention, as well as his appearance on the Tom Woods Show.Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.Jeremy Kauffman's appearance on the Tom Woods Show. His address to the LP national convention.Jeremy's interview on BMS ep. 368.This episode's sponsor, the free Plan-B guide from ExPatMoney.The "Universal Principles of Liberty."The HamanNature substack.Help support the Bob Murphy Show.

At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics' Chinese partner Akeso stole the show. For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso's clinical trial in China will hold up in a global population.Immuneering, BMS/BioNTech, Merck, Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China's Innovent Biologics as it seeks to bolster its oncology pipeline. Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We'll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.

On this week's episode, Chris Garabedian, Brian Skorney, Graig Suvannavejh, and special guest Ginkgo Bioworks CEO, Jason Kelly, kick off with a market update, highlighting a continued positive sentiment, citing Endpoints' recent Biopharma Sentiment Index survey results, which showed improvements in biopharma conditions. The co-hosts also note the continued IPO activity, including Kardigan's recent filing. The conversation shifts to China, with Jason suggesting that genetic engineering is a strategic technology extending beyond therapeutics, warning that the U.S. is offshoring critical innovation to China. This sparks a debate with others noting that global collaboration is embedded in drug development and questioning whether restricting partnerships would ultimately harm U.S. competitiveness. In deals, the group highlights Lilly's acquisition of three vaccine companies for up to $3.8 billion and Apogee's $1.3 billion strategic collaboration with Blackstone to advance their eczema drug. The conversation shifts to data, with GSK's Phase 3 data for chronic hepatitis B drug, and an overview of datasets at ASCO 2026, including Revolution Medicines Phase 3 trial results for pancreatic cancer, which are expected to be the headline of the conference. The episode concludes with an overview of Biohaven's R&D Day, BMS in multiple myeloma, Dyne's DMD, and updates on the FDA following the recent leadership changes. after the departure of Dr. Marty Makary. *This episode aired on May 29, 2026. 

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients.  They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies.    Episode Timestamps:  00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray.  00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints.  00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival.  00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead.  00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer.  00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies.  00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy.  00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit    Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Alex Gray;  LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/    Keep up with David Radwaner;  LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/    Keep up with Tom Brockbank;  LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/      Follow IDEA Pharma On; Website: https://www.ideapharma.com/    Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

With co-author Chris Coyne, Abby Hall has a new book serving as an introduction to the Austrian School. As she and Bob discuss, the book fills a niche in the existing options of this genre.Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.Abby Hall's new book (co-authored with Chris Coyne), Austrian Economics: An Introduction.The prior BMS interview of Abby (on Latin American military intervention).Help support the Bob Murphy Show.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend!   I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Emily: Hi Dr Cabral, you are just such an amazing soul! Keep doing gods great work! I'm writing in to ask about my personal situation, I am 34, I had a throat cancer back in 2019, underwent radiation and surgery. Since then I had 2 babies, and came down with autoimmune symptoms this last year 2025. Since then I dove into healing myself, finished a gut program, did "big 5" labs, just did a 3 month mold detox. I am a year out and my food sensitivities are gone, brain fog gone, gut healed. But what is remaining is rosacea still, and I just did a teeth cleaning and we are still seeing inflamed gums. I am working with a practitioner and we know I have some viruses to tackle next and boost my immune system. At this point is there anything more you would add, to help me get rid of remaining rosecea?      Ashley: Hi Dr. Cabral! I installed the hydrogen water device you recommended in my home last summer. My family loves it, however whenever I personally drink the water I get SEVERELY constipated. I have run 4 tests now over the last 6 months and every time I reintroduce the water (even at a low pH and titrating up as advised by your team) the constipation returns. Ironically the very first week I tried the water I was having 3-4 BMs a day before the constipation trend began. Do you have any ideas what could be going on? I'm an IHP-L2 and have consulted your team and the support groups, but everyone seems perplexed... hence my outreach to you directly on this one. Note I did the CBO protocol 2x last yr for recurring gut infections before uncovering I have mold toxicity & am now on this protocol.      Brett: Hi Dr. Cabral—I'm seeking guidance on refractory hypercoagulability. I've had 77 DVTs and 33 pulmonary emboli, and was diagnosed with antiphospholipid syndrome two years ago. Despite therapeutic anticoagulation with daily Arixtra (fondaparinux), I continue to develop thrombotic events. Are there evidence-informed adjunct strategies (e.g., anti-inflammatory protocols, micronutrient optimization, endothelial support, or additional labs) that may help reduce clot recurrence alongside standard care? I remain under physician management but am exploring complementary approaches to improve outcomes. Thank you.       Kay: Dear Dr. Cabral- Thank you so much for the work you are doing and all your super informative podcasts. I took the Minerals & Metals test end of 2024 which showed high mercury and aluminum so in November of 2025 I had all 4 of my mercury amalgams removed by a biological dentist who is SMART certified. After removal, I did my Heavy Metal Detox for 8 weeks. I then retested at the beginning of April and just received my test results and was dismayed to see Mercury levels exactly the same and the aluminum slightly higher, even. Several other minerals were off balance as well. My question to you is how long would it take to detox from amalgam removals and should I do another heavy metal detox? Or did I retest too early? Appreciate your help, Kay       Kay: Hi Dr Cabral, Recently I had conventional bloodwork labs done and repeated (Mar 31st, April 3rd) testing high in magnesium levels (2.4 mg/dL and 2.5 mg/dL, respectively) and experienced symptoms of palpitations at night. My functional medicine Dr told me to stop taking any supplements/nutritional beverages containing Mg (i.e. CALM Mg powder) which I did. Even more of a surprise was when I received my recent Minerals & Metals test back, done around the same time as my blood tests, showing that I had an elevated Ca/Mg ratio (7.9) indicating relative Mg deficiency and elevated Na/Mg ratio (5.3) also indicating a relative Mg deficiency. How could both of these labs be true? Could stress play a factor? I recently moved and am caring for parents, 1 who has been Dx'd w/cancer.     Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right!   - - - Show Notes and Resources: StephenCabral.com/3761 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Jacob Townsend talks to Jeff Birchfield, of Six Rivers Media, about the passing of Kyle Busch, his career, legacy, success at BMS, and more.See omnystudio.com/listener for privacy information.

Hour 4 of May 22, 2026 Jacob Townsend talks to Jeff Birchfield, of Six Rivers Media, about the passing of Kyle Busch, his career, legacy, success at BMS, and more. Then, he discusses a split of opinions in the SEC about whether or not to go to 24 team College Football Playoff. Also, he talks about Greeneville playing in state championship today and the Lady Vols getting ready for the second game of their Super Regional. See omnystudio.com/listener for privacy information.

Agentic AI is growing in its applications. Google DeepMind and Edison are leveraging the growing capabilities by developing AI Scientists. These platforms are poised to streamline the scientific process, aiding human scientists with a variety of tasks. Meanwhile, despite positive data in its Phase III DMD therapy trial, Regenxbio's stock fell for a variety of reasons. 10X Genomics and Harvard University are suing Element Biosciences over patents for a multiomics platform. Finally, Bristol Meyers Squibb is partnering with Hengrui Pharma to develop 13 early-stage programs with the potential to grow their investment to a predicted $15 billion in sales. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: Google DeepMind and Edison Are Building the AI Scientist By Fay Lin, PhD, GEN Edge, May 19, 2026StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy CandidateBy Alex Philippidis, GEN Edge, May 17, 2026 10x Genomics, Harvard Target Element's Multiomics Platform in Patent Lawsuit By Alex Philippidis, GEN Edge, May 12, 2026 BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration By Alex Philippidis, GEN Edge, May 13, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Precision Medicine SummitJoin us June 3, 2026 Hosted on Acast. See acast.com/privacy for more information.

C'est mieux de faire BMS, streamer tous les jours et de vendre des tee shirts de manière imparfaite que de travailler à l'usine à tout jamais.Dans ce podcast Joël BMS est passé dans le cockpit pour une conversation délicieuse de 3H... au menu dans l'avion : il a avoué de vrais secrets, nous a parlé de son amour pour les jeux vidéos, internet, et ses frères qui l'accompagne dans ses aventures.Lien de notre offre avec Trade Republic : https://chck.me/m63k 30€ d'actions offertes chez des marques qu'on kiffe genre adidas, Uniqlo etc.. dès la création d'un nouveau compte via le lien (faudra juste créditer 100 euros sur ton compte et faire 2 investissements de 1€ minimum)Collaboration commercialeInvestir comporte des risques, notamment le risque de perte de capital. Les performances passées ne préjugent pas des performances futures ! Pour plus d'informations, consultez les conditions spécifiques directement accessibles sur le site Internet de Trade RepublicOn est en live tous les lundi mardi et mercredi à partir de 18h sur Twitch & Youtube !https://www.twitch.tv/caminotv?lang=fr + / @caminotv Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically rich conversation on leadership, commercialization, and the future of neuropsychiatry. From starting as a pharmacist in the UK to pivoting from R&D into commercial leadership at Johnson & Johnson, rising through Bristol Myers Squibb, and ultimately stepping into her first biotech CEO role at Acadia, Catherine shares how storytelling became the throughline of her career—transforming science into physician trust, investor conviction, and enterprise vision. In this episode, Catherine opens up about the personal family experiences with neurodegenerative disease that made Acadia's focus on CNS and rare disease feel like her “Goldilocks opportunity.” She offers a candid look at the realities of being a first-time CEO, managing investor ecosystems, building the right C-suite, balancing billion-dollar commercial execution with high-risk R&D, and navigating the emotional stakes of developing therapies for Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and beyond. Rahul and Catherine also explore the seismic shifts reshaping biotech—from AI-powered commercialization and patient services to policy advocacy through BIO, FDA modernization, and the strategic pressures facing CNS innovation. This episode is both a masterclass in biotech leadership and a powerful reminder that the best CEOs don't just run companies—they tell stories that move science, markets, and patients forward. Biography: Ms. Owen Adams joined Acadia as Chief Executive Officer and as a member of our Board of Directors in September 2024. Ms. Owen Adams has over 25 years of executive level experience in the pharmaceutical industry. Prior to joining Acadia, Ms. Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb (BMS), where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology. Previously, Ms. Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS, where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS's merger with Celgene. Prior to her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson (J&J), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Ms. Owen Adams began her career in R&D and manufacturing at AstraZeneca. Ms. Owen Adams currently serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms. Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a non-profit organization. Ms. Owen Adams earned a BSc. in Pharmacy from the University of Manchester, becoming a qualified pharmacist and member of the Royal Pharmaceutical Society (MRPhS).

La batería de un coche eléctrico no es un componente estático; es un laboratorio químico en constante ebullición y, lamentablemente, tiene fecha de caducidad. En este vídeo abrimos la "caja negra" de la degradación para explicar por qué el depósito de los coches eléctricos "encoge" con el tiempo y qué puedes hacer para evitarlo. ¿Qué es realmente la degradación? A diferencia de un motor de combustión, donde el depósito siempre tiene el mismo tamaño, las baterías de iones de litio sufren dos tipos de castigo constantes: -Degradación por calendario: El simple paso del tiempo oxida los componentes internos, incluso si el coche está parado en el garaje. -Degradación por ciclo: El estrés mecánico de cargar y descargar expande y contrae los materiales, generando microfisuras en los electrodos. Según datos actualizados a 2026, la pérdida media de capacidad se sitúa en un 2,3% anual. Esto significa que, en diez años, tu coche habrá perdido casi una cuarta parte de su autonomía original. Los tres enemigos de tu autonomía Para maximizar la vida útil de las celdas, debemos vigilar tres factores críticos: -El Calor: El litio sufre fuera de los 15°C - 35°C. El calor extremo acelera la descomposición del electrolito, creando una capa de "colesterol químico" que atrapa los iones y los deja inservibles. -La Carga Ultrarrápida: El uso sistemático de cargadores de más de 100 kW duplica la velocidad de degradación en comparación con la carga doméstica. Es un estrés térmico que la química paga caro. -Estados de Carga Extremos: Mantener el coche al 100% durante días o bajar habitualmente del 5% genera inestabilidad química y riesgos de fallos de voltaje permanentes. El peligro oculto: Las Dendritas Uno de los secretos mejor guardados es la formación de dendritas. Estas estructuras ramificadas crecen cuando se abusa de la carga rápida, especialmente en frío. Si una de estas "agujas" metálicas perfora el separador interno, se produce un cortocircuito que puede derivar en un incendio químico de extrema dificultad de extinción. La trampa del software (SOH) El "State of Health" o salud de la batería es un dato calculado por el software del fabricante (BMS). Hemos detectado casos donde las actualizaciones de software "maquillan" este porcentaje, liberando capacidad de reserva oculta para que el usuario no note la degradación real. Es vital certificar la salud de la batería con herramientas externas antes de comprar un eléctrico de segunda mano. Decálogo de Supervivencia: Cómo estirar la vida de tu batería Para evitar facturas de reemplazo que pueden oscilar entre los 7.000 € en coches urbanos hasta más de 25.000 € en modelos premium, sigue estos consejos: -Regla del 20-80: Mantén el uso diario en este rango. -Carga lenta: Prioriza siempre la carga en casa (AC). -Evita el 100% estático: Si cargas al máximo, que sea justo antes de salir de viaje. -Preacondicionamiento: Calienta la batería en invierno antes de circular o cargar. -Aparca a la sombra: Evita que el suelo caliente "cocine" las celdas. -Conducción suave: Evita picos de descarga por aceleraciones bruscas. -No llegues al 0%: Podrías dejar la batería en un estado de "sueño profundo" irreversible. -Freno regenerativo: Úsalo para recuperar energía de forma suave. -Actualizaciones: Mantén el software al día para mejorar la gestión térmica. -Certificación real: Usa dispositivos OBD2 para conocer el estado real de la química. La movilidad eléctrica actual exige un usuario consciente. Mientras no lleguen las baterías de estado sólido a finales de esta década, cuidar la química es la única forma de evitar que tu coche se convierta en un gasto inasumible.

Adam Haman returns to help Bob respond to Martyr Made's recent appearance on Jacob Winograd's Biblical Anarchy podcast.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.Darryl's appearance on Jacob Winograd's show.A previous BMS covering Oregon's drug decriminalization.This episode's sponsor, The Swan Brothers.The HamanNature substack.Help support the Bob Murphy Show.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! En este episodio de La Ola Eléctrica nos adentramos en uno de los temas más importantes, y a la vez menos comprendidos, del coche eléctrico: las baterías. Durante décadas, el motor fue el corazón del automóvil. Pero en la era eléctrica, el centro de poder se ha desplazado bajo el suelo del vehículo. La batería decide la autonomía, el precio, la carga rápida, la vida útil, la seguridad, el peso y hasta la estrategia industrial de países enteros. Hablamos de cómo funciona una batería de coche eléctrico, qué elementos la componen, qué papel tienen el ánodo, el cátodo, el electrolito, el separador y el BMS, y por qué no todas las baterías son iguales. Analizamos las principales tecnologías actuales: LFP, NCM, NCA, LMFP, baterías de sodio y las prometedoras baterías de estado sólido. También explicamos por qué China ha tomado tanta ventaja con gigantes como CATL y BYD, por qué Europa ha reaccionado tarde, qué papel juegan materiales como el litio, el níquel, el cobalto, el grafito o el sodio, y por qué el reciclaje será clave en la próxima década. Un episodio para entender que la batería no es solo un componente más del coche eléctrico: es el nuevo motor, el nuevo campo de batalla industrial y una de las claves que decidirán qué marcas y qué países liderarán la movilidad del futuro.Escucha este episodio completo y accede a todo el contenido exclusivo de Somos Eléctricos. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/627406

Podcast: PrOTect It All (LS 27 · TOP 10% what is this?)Episode: Cyber Risk in Construction: Securing AEC Projects in a Digital, AI-Driven WorldPub date: 2026-04-27Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationConstruction sites are no longer just physical - they're digital, connected, and increasingly vulnerable. In this episode of Protect It All, host Aaron Crow sits down with Lee Carsten to explore the rising cyber risks across the architecture, engineering, and construction (AEC) industry. As digital transformation accelerates - with AI, digital twins, and connected building systems becoming standard - construction projects are expanding their attack surface in ways many organizations don't fully understand. Aaron and Lee unpack the unique challenges facing AEC environments, from fragmented systems and evolving workflows to the growing need for integrating cybersecurity into business decisions - not just IT functions. You'll learn: Why construction and infrastructure projects are becoming prime cyber targets How digital transformation and AI are reshaping risk in AEC environments The role of building management systems (BMS) and OT in modern projects Why foundational controls and human awareness still matter most How to align cybersecurity with real-world construction workflows Practical strategies to build resilience into projects from day one Whether you're in construction, engineering, IT, or OT security, this episode delivers real-world insights to help you protect the infrastructure we rely on every day. Tune in to learn how to secure modern construction in a connected world - only on Protect It All. Key Moments:  05:39 Importance of interpersonal skills 08:08 Construction security and recent projects 11:46 Challenges in AEC industry adoption 19:30 Importance of disaster recovery 20:31 Discussing costs of business interruptions 24:06 RFP process and bid management 27:25 Complexity of building projects 32:02 FBI investigation triggers and readiness 36:55 Managing complex building assets 39:37 Choosing durable equipment and future tech 42:01 Understanding OT data for security About the guest :  Lee Carsten's journey in technology began in the era of punch cards - painstakingly sorted and fed into compilers, where a single fumble could mean hours' worth of work undone. Lee studied COBOL in college, envisioning a future as a programmer. That path nearly led to Walmart, where Lee's mother worked on the company's pioneering buyer decision support system under Randy Mott. While the family connection and an offer from Kevin Turner to join a new team were tempting, Lee ultimately decided against moving to Bentonville and working for $18,000 annually. This early exposure to large-scale business technology, combined with pivotal career choices, shaped Lee Carsten's perspective on IT and the evolving world of software development. How to connect Lee: https://www.linkedin.com/in/leecarsten/ Website: https://whitecaprisk.com/ Connect With Aaron Crow: Website: www.corvosec.com  LinkedIn: https://www.linkedin.com/in/aaronccrow Learn more about PrOTect IT All: Email: info@protectitall.co  Website: https://protectitall.co/  X: https://twitter.com/protectitall  YouTube: https://www.youtube.com/@PrOTectITAll  FaceBook:  https://facebook.com/protectitallpodcast To be a guest or suggest a guest/episode, please email us at info@protectitall.co Please leave us a review on Apple/Spotify Podcasts: Apple   - https://podcasts.apple.com/us/podcast/protect-it-all/id1727211124 Spotify - https://open.spotify.com/show/1Vvi0euj3rE8xObK0yvYi4The podcast and artwork embedded on this page are from Aaron Crow, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

This week, Jimmy and Tyler catch up on two very different 4Runner projects — and somehow both of them involve things that were bent, broken, or seized in ways nobody’s seen before. Jimmy’s 4Runner “Samantha” is making progress. He spent the week fabricating temporary shock towers out of scrap steel, getting the shocks roughly mounted, and articulating the suspension to figure out how much travel he’s actually working with. The verdict: he needs to raise the shocks about a half inch, the bump stops are in the right ballpark, and the Panhard bar collision he was worried about looks like it won’t be an issue once the setup is dialed. He also talks through the surprisingly useful difference between working with metal vs. wood — and why metal scrap is genuinely hard to throw away. Tyler’s 4Runner “The Mule” went to Jason at OCD Innovations for a full teardown, and what they found was wild. The pinion bearing had seized and welded itself to the housing — which is what caused the axle lockup and the subsequent catastrophic failure. The good news: the Mile Marker hubs actually survived and held. The not-so-good news: basically everything else needed replacing — lower links (bent aluminum), upper link bracket, CV joints (Metal Cloak), steering kit (Sidetrack Off Road), DOM tubing for the track link and Panhard bar, and a driveshaft joint that exploded and saved the front diff case in the process. The one remaining unknown is the rear diff. Jason is being thorough — almost comically so — and the mule is back on four wheels, running under its own power. Registration still has to happen, which means blinkers, safety inspection, and a Switch-Pros wiring job are all still on the list. They also get into a deep conversation on lithium battery setups — starter battery vs. auxiliary battery, how alternators interact with lithium BMS shutoffs, and why Tyler is landing on a Dakota Lithium battery with a DC charger as his power management strategy. Off the trail: Jimmy went and saw *Project Hail Mary* in theaters and loved it (verdict: great home watch, doesn’t require the big screen). He ran a 10K at the Run Rockland event and surprised himself with a 9:45/mile average. And both Jimmy and Tyler took a moment to geek out over the Big Boy steam locomotive #4014 rolling through Roseville — 1.2 million pounds, 133 feet long, 7,000 horsepower, and apparently enough to stop traffic and make kids forget trains exist in favor of radio towers. SnailTrail4x4 Discord: https://discord.gg/yFyFFkQbuyCome hang out with us on the SnailTrail4x4 Discord — it’s the easiest way to connect with Tyler and Jimmy directly, chat with fellow offroad enthusiasts, and get first access to Group Buys and Treasure Hunt token drops. Group Buy for the Devos LightRanger 500We reached out to Devos, and they are in. Here’s how the discount tiers work: 10 people → 15% off (~$60/light) 20 people → 20% off (~$56/light) 30+ people → 25% off (~$52/light) These retail at $70. To get in, just send us your email and how many units you want. You can email us at jimmy@snailtrail4x4.com or tyler@snailtrail4x4.com, or DM us on Instagram. Deadline: April 30th. Want to learn more about the LightRanger 500? Click Here: https://www.devosoutdoor.com/products/lightranger-500 MORRFlate Giveaway at 900 Reviews on Apple Podcast. But our next giveaway is when we reach 800 reviews; we are giving away an OnX Elite Membership. We will also give away an OnX Elite membership when we get to 850. However, when we reach 900 Reviews, we are teaming up with MORRFlate for a $1000 MF Product Giveaway. Go over to Apple Podcasts to leave your review now and become eligible to win. Congratulations to A13XMONT, who won a set of tires from Yokohama Tire! Call us and leave us a VOICEMAIL!!! We want to hear from you even more!!! You can call and say whatever you like! Ask a question, leave feedback, correct some information about welding, say how much you hate your Jeep, and wish you had a Toyota! We will air them all, live, on the podcast! +01-916-345-4744. If you have any negative feedback, you can call our negative feedback hotline, 408-800-5169. 4Wheel Underground has all the suspension parts you need to take your off-road rig from leaf springs to a performance suspension system. We just ordered our kits for Kermit and Samantha and are looking forward to getting them. The ordering process was quite simple, and after answering the questionnaire, we ensured we got the correct and best-fitting kits for our vehicles. If you want to level up your suspension game, check out 4Wheel Underground. SnailTrail4x4 Podcast is brought to you by all of our peeps over at irate4x4! Make sure to stop by and see all of the great perks you get for supporting SnailTrail4x4! Discount Codes, Monthly Give-Always, Gift Boxes, the SnailTrail4x4 Community, and the ST4x4 Treasure Hunt! Thank you to all of those who support us! We couldn’t do it without you guys (and gals!)! SnailSquad Monthly Giveaway For the Month of April, we are giving away Gift Boxes. Its Gift Box month and two luck indiviuals will win a one of our gift boxs. These are jam packed with goodies from tools to whiskey smokers. They are always different and always random. If you want a chance to win, sign up for the Giveaway Tier on Irate4x4 Congrats to Roger Lutz on March’s Giveaway. We gave away the new Devos LightRanger500. This little light is jam-packed with features, from red, orange, and white lights to a motion sensor. It would be perfect for inside a tent, under a canopy, or just general use around the vehicle. If you want a chance to win, sign up for the Giveaway Tier on Irate4x4 Listener Discount Codes: SnailTrail4x4 –SnailTrail15 for 15% off SnailTrail4x4 MerchMORRFlate – snailtraill4x4 to get 10% off MORRFlate Multi Tire Inflation Deflation™ Kits4WheelUnderground – snailtrail 10% offIronman 4×4 – snailtrail20 to get 20% off all Ironman 4×4 branded equipment!Sidetracked Offroad – snailtrail4x4 (lowercase) to get 15% off lights and recovery gearSpartan Rope – snailtrail4x4 to get 10% off sitewideShock Surplus – SNAILTRAIL4x4 to get $25 off any order!Mob Armor – SNAILTRAIL4X4 for 15% offSummerShine Supply – ST4x4 for 10% offBackpacker’s Pantry – Affiliate LinkLaminx Protective Films – Use the Link to get 20% off all products (Affiliate Link) Show Music: Outroll Music – Meizong Kumbang Midroll Music – ComaStudio

Bob continues his commentary on John chapter 3, this time on verses 18 through 36 (finishing the chapter). The emphasis is on the humility of John the Baptist, and the fact that you need a savior.Mentioned in the Episode and Other Links of Interest:The previous episode in this series, i.e. BMS ep 487, Installment 11: Whoever Believes in Him.RC Sproul on Jesus as the light.Help support the Bob Murphy Show.

If you've ever found yourself wondering, "What is happening to me?"… you are not alone. Perimenopause can feel like a slow and disorienting shift. In this honest and empowering episode, I'm joined by Dr Charlotte Gooding, GP and BMS-accredited menopause specialist, to explore perimenopause, HRT and breast cancer risk. We unpack the symptoms many women miss, the emotional impact of hormonal change, and the nuance around HRT safety, so you can make more informed, personalised decisions about your health. If you're navigating perimenopause, HRT decisions, or breast cancer fears, this episode will help you feel more informed, empowered and less alone. More details: https://luminate-group.co.uk/podcast/183 Connect on LinkedIn Here  Follow on Instagram Here  Love the Wisdom For Working Mums Podcast? Let's take the conversation further. Subscribe for exclusive insights delivered straight to your inbox - designed to support you in leading with confidence and living with intention. 

Nard engages with the BMS chatroom and basically becomes a listener, cheat fantasies and more!

This Biotech CEO Created The RedTail Platform To Fight Cancer. Guest:Eric PomaCEO of Calidi Bio CLDI Company Name:Calidi BiotherapeuticsWebsite: https://www.calidibio.com/Ticker: NYSE: CLDIEric's Bio:Eric Poma, Ph.D. has served as Chief Executive Officer and board director of Calidi since April 2025 and brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of capital fundraising, big pharma collaboration agreements, and clinical program development.Prior to joining Calidi, Dr. Poma served as CEO of Molecular Templates (NASDAQ: MTEM), a clinical-stage biotech focused on the development of a novel class of therapeutic agents with unique biology in oncology. At Molecular Templates he raised over $250 million in equity financing and secured over $150 million in strategic capital through agreements with Takeda, Vertex and BMS. He previously served as Vice President, Business Development of Innovive Pharmaceuticals. Prior to that he held various senior level positions at Imclone Systems, Inc., primarily in business development. Earlier, Dr. Poma served as a Healthcare & Biotechnology Analyst with the healthcare fund Eagle Growth Investors, LLC.Dr. Poma received a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill, an M.B.A. from the Leonard N. Stern School of Business and a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill.Company Bio:Calidi Biotherapeutics is a biotechnology company pioneering the development of targeted genetic medicines for cancer and other diseases through its RedTail platform. The company's lead compound, CLD-401, is a systemically delivered oncolytic virus that expresses high levels of IL-15 superagonist only in the tumor microenvironment. The company expects to file an IND to initiate clinical studies for CLD-401 by the end of 2026. The company continues to advance what the RedTail platform can achieve and will be presenting additional data throughout the year.

Hour 4 of April 6, 2026 Jacob Townsend talks with Deb Williams, of Autoweek.com, about the weekend at Rockingham, the first two months of the new points format, looking ahead to Bristol, the future of the spring race at BMS, Darius Rucker ownership of Legacy Motors, and more. Then, he is joined by President of Bristol Motor Speedway, Jerry Caldwell, about the race weekend, Tyler Reddick, 23XI Racing, Fan Zone, GPS Navigator Tool, dignitaries, and more. Also, Jacob gives his national championship pick. See omnystudio.com/listener for privacy information.

Jacob Townsend talks with Deb Williams, of Autoweek.com, about the weekend at Rockingham, the first two months of the new points format, looking ahead to Bristol, the future of the spring race at BMS, Darius Rucker ownership of Legacy Motors, and more.See omnystudio.com/listener for privacy information.

Te vamos a contar toda la verdad en 2026. ¿Es cierto que un fallo en la batería significa el fin de la vida útil de un coche eléctrico? Esta es la pregunta del millón que frena a muchos compradores y quita el sueño a otros tantos. La creencia popular dice que cualquier avería en el acumulador de energía implica un gasto de 20.000 euros o el desguace inmediato, pero la realidad técnica y financiera es mucho más compleja y, afortunadamente, más optimista. La anatomía de la "caja negra" Para entender si una batería se puede reparar, primero hay que saber qué hay dentro. No estamos ante un bloque sólido e indivisible. Una batería de tracción se compone de tres niveles: las celdas (la unidad mínima), los módulos (agrupaciones de celdas) y el pack (el conjunto total con su carcasa, refrigeración y el cerebro electrónico o BMS). En la mayoría de los casos, "reparar" consiste en identificar el módulo defectuoso y sustituirlo, evitando el coste astronómico de cambiar el pack completo. La economía de la reparación La decisión de reparar no es solo técnica, es puramente financiera. En 2026, los precios de las baterías han bajado significativamente, rondando los 130-150 €/kWh. Por ejemplo, una batería nueva de un Renault ZOE puede costar unos 7.500 €, mientras que la de un VW ID.4 sube hasta los 16.500 €. Si la sustitución de un módulo ronda los 2.000 €, el ahorro es evidente. Sin embargo, hay que tener en cuenta el "State of Health" (SOH) o estado de salud general. Si el resto de la batería está muy degradado, poner un módulo nuevo es inútil, ya que se descompensará rápidamente con los antiguos. Arquitectura y reparabilidad: No todos los coches son iguales Aquí es donde los fabricantes toman caminos distintos. El diseño del coche determina si la reparación es sencilla o una pesadilla: -BMW i3: Un ejemplo de diseño inteligente con 8 módulos independientes y accesibles. -Grupo Hyundai/Kia: Su plataforma E-GMP permite sustituir secciones con relativa facilidad, bajando costes de mano de obra. -Tesla (Model Y con celdas 4680): El polo opuesto. Al usar baterías estructurales rellenas de resina (foam) para dar rigidez, la reparación es prácticamente imposible. Si falla, se cambia el pack entero. -Toyota y Lexus: Especialistas en longevidad, sus baterías de níquel-metal hidruro son las más reparadas del mundo gracias a su sencillez. Curiosidades y el futuro del sector El debate sobre la reparación no es nuevo. Ya en 1900, el Lohner-Porsche (el primer híbrido) sufría con sus pesadas baterías de plomo. Hoy, vemos fenómenos como los "Tesla resucitados" en Europa del Este, donde mecánicos expertos y hackers consiguen reparar packs que la propia marca da por perdidos, "engañando" al software para devolver los coches a la carretera. Mirando al futuro, las baterías de estado sólido prometen más autonomía, pero plantean un reto: al ser bloques sólidos, su reparabilidad podría ser nula. Por contra, gigantes como CATL están estandarizando módulos para que los talleres independientes puedan comprar recambios originales, lo que reduciría los costes de reparación hasta un 80%. ¿Cuándo es mejor no intentar la reparación? Existen tres escenarios donde lo más sensato es desistir: -Degradación uniforme: Si todas las celdas están agotadas por igual. -Daños por inundación: La corrosión interna por agua es un "cáncer" imposible de frenar en el litio. -Coste excesivo: Si la factura supera el 60% del valor venal del coche. En conclusión, reparar una batería es hoy una opción real y viable siempre que el fallo sea localizado y el resto del conjunto esté sano. La "muerte" de la batería ya no es el fin del coche, sino una avería importante pero gestionable dentro del nuevo ecosistema de la movilidad eléctrica.

In this episode, we welcome Kirollos Hanna, PharmD, BCPS, BCOP, a recognized leader in oncology pharmacy practice and research. Dr. Hanna shares insights into the evolving landscape of antibody-drug conjugates (ADCs) and the unique challenges they present in managing chemotherapy-induced nausea and vomiting (CINV).  As ADC use expands, oncology teams are observing new and sometimes underrecognized patterns of nausea and vomiting, particularly with HER2-directed therapies and delayed-phase symptoms that extend beyond the traditional monitoring window. This discussion highlights how these patterns differ from conventional chemotherapy and what that means for clinical practice.  Dr. Hanna also reviews emerging pharmacokinetic data and clinical trial evidence supporting the use of NK1 receptor antagonist–based antiemetic strategies. The conversation emphasizes practical, actionable approaches for optimizing supportive care, improving patient quality of life, and ensuring proactive symptom management within the medically integrated oncology team.  Learning Objectives:  Describe emerging patterns of chemotherapy-induced nausea and vomiting (CINV) associated with antibody–drug conjugates (ADCs), with emphasis on HER2-directed ADCs and delayed-phase nausea beyond day 5  Discuss pharmacokinetic and clinical trial evidence on NK1 receptor antagonist–based antiemetic strategies when optimizing CINV prevention for patients receiving ADC therapy.  This episode offers 0.5 CE credit hours to pharmacists and pharmacy technicians. Claim CE credit here. Guest: Kirollos Hanna, PharmD, BCPS, BCOP, Director of Pharmacy, Minnesota Oncology, Assistant Professor of Pharmacy, Mayo Clinic College of Medicine, Associate Editor, Journal of the Advanced Practitioner in Oncology (JADPRO)  Disclosures: Speaker: BeOne, BMS, Exelixis, Pfizer Consulting Fees: BeOne, BMS, Exelixis, Pfizer, Astrazeneca

Bob was recently on the "What Is Money?" podcast to probe the philosophical underpinnings of Austrian economics.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.HHH's Economic Science and the Austrian Method (ESAM).BMS ep 7 explaining Godel's theorem.Bob's earlier appearance on "What Is Money?" (recorded on-site at the inaugural ARC conference).Help support the Bob Murphy Show.

Te vamos a contar toda la verdad en 2026. ¿Es cierto que un fallo en la batería significa el fin de la vida útil de un coche eléctrico? Esta es la pregunta del millón que frena a muchos compradores y quita el sueño a otros tantos. La creencia popular dice que cualquier avería en el acumulador de energía implica un gasto de 20.000 euros o el desguace inmediato, pero la realidad técnica y financiera es mucho más compleja y, afortunadamente, más optimista. La anatomía de la "caja negra" Para entender si una batería se puede reparar, primero hay que saber qué hay dentro. No estamos ante un bloque sólido e indivisible. Una batería de tracción se compone de tres niveles: las celdas (la unidad mínima), los módulos (agrupaciones de celdas) y el pack (el conjunto total con su carcasa, refrigeración y el cerebro electrónico o BMS). En la mayoría de los casos, "reparar" consiste en identificar el módulo defectuoso y sustituirlo, evitando el coste astronómico de cambiar el pack completo. La economía de la reparación La decisión de reparar no es solo técnica, es puramente financiera. En 2026, los precios de las baterías han bajado significativamente, rondando los 130-150 €/kWh. Por ejemplo, una batería nueva de un Renault ZOE puede costar unos 7.500 €, mientras que la de un VW ID.4 sube hasta los 16.500 €. Si la sustitución de un módulo ronda los 2.000 €, el ahorro es evidente. Sin embargo, hay que tener en cuenta el "State of Health" (SOH) o estado de salud general. Si el resto de la batería está muy degradado, poner un módulo nuevo es inútil, ya que se descompensará rápidamente con los antiguos. Arquitectura y reparabilidad: No todos los coches son iguales Aquí es donde los fabricantes toman caminos distintos. El diseño del coche determina si la reparación es sencilla o una pesadilla: -BMW i3: Un ejemplo de diseño inteligente con 8 módulos independientes y accesibles. -Grupo Hyundai/Kia: Su plataforma E-GMP permite sustituir secciones con relativa facilidad, bajando costes de mano de obra. -Tesla (Model Y con celdas 4680): El polo opuesto. Al usar baterías estructurales rellenas de resina (foam) para dar rigidez, la reparación es prácticamente imposible. Si falla, se cambia el pack entero. -Toyota y Lexus: Especialistas en longevidad, sus baterías de níquel-metal hidruro son las más reparadas del mundo gracias a su sencillez. Curiosidades y el futuro del sector El debate sobre la reparación no es nuevo. Ya en 1900, el Lohner-Porsche (el primer híbrido) sufría con sus pesadas baterías de plomo. Hoy, vemos fenómenos como los "Tesla resucitados" en Europa del Este, donde mecánicos expertos y hackers consiguen reparar packs que la propia marca da por perdidos, "engañando" al software para devolver los coches a la carretera. Mirando al futuro, las baterías de estado sólido prometen más autonomía, pero plantean un reto: al ser bloques sólidos, su reparabilidad podría ser nula. Por contra, gigantes como CATL están estandarizando módulos para que los talleres independientes puedan comprar recambios originales, lo que reduciría los costes de reparación hasta un 80%. ¿Cuándo es mejor no intentar la reparación? Existen tres escenarios donde lo más sensato es desistir: -Degradación uniforme: Si todas las celdas están agotadas por igual. -Daños por inundación: La corrosión interna por agua es un "cáncer" imposible de frenar en el litio. -Coste excesivo: Si la factura supera el 60% del valor venal del coche. En conclusión, reparar una batería es hoy una opción real y viable siempre que el fallo sea localizado y el resto del conjunto esté sano. La "muerte" de la batería ya no es el fin del coche, sino una avería importante pero gestionable dentro del nuevo ecosistema de la movilidad eléctrica.

Michael Fraser is a business consultant on leading LLMs, with an extensive knowledge of praxeology. He joins Bob to discuss the Pentagon's decision to sever ties with Anthropic and even designate them a supply chain risk.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.Anthropic CEO's statement in response to Hegseth decision.Academic paper putting leading LLMs into a wargame.Good examples of "jailbreaking" safeguards on LLMs.The BMS interview of Steve Landsburg discussing Grothendiek.Michael Fraser's interview on the InFi podcast, discussing LLMs as a cauldron, not a crystal ball.Help support the Bob Murphy Show.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.We start with a significant personnel change at the FDA, where Vinay Prasad, M.D., is set to depart by the end of April. Known for his contentious interactions with the biopharma industry, particularly concerning vaccines and cell and gene therapies, his departure may signal shifts in regulatory priorities and approaches. Industry stakeholders are closely watching how his exit will affect upcoming decisions and relations between regulatory bodies and biopharma companies.In a strategic collaboration, Novo Nordisk and Hims & Hers have settled their public disputes by agreeing to distribute Novo's Ozempic and Wegovy through Hims' telehealth platform. This partnership highlights the increasing importance of digital health platforms in expanding medication access, particularly for chronic conditions like obesity and diabetes. This trend reflects a broader movement where legacy pharmaceutical companies are turning to digital avenues to enhance patient reach.On the clinical trial front, Ipsen has decided to halt the development of its lymphoma drug Tazverik after safety concerns were raised by an independent data monitoring committee. This decision underscores the rigorous safety standards in place for clinical trials and the ongoing challenge of balancing potential therapeutic benefits against safety risks. Similarly, Roche's oral SERD giredestrant failed to meet its primary endpoint in a phase 3 trial for first-line breast cancer treatment, raising questions about the limits of selective estrogen receptor degraders despite previous successes in adjuvant and second-line settings. The complexity of translating promising mechanisms into consistent clinical outcomes across different stages of treatment is highlighted here.Regulatory challenges remain a significant theme, with Novo Nordisk's Indiana plant facing scrutiny that led to the FDA rejecting Incyte's application for Zynyz as a first-line treatment for non-small cell lung cancer. This incident underscores how manufacturing issues can heavily impact drug approval processes and highlights the critical nature of compliance with regulatory standards.In terms of new drug approvals, Bristol Myers Squibb has received FDA approval for Sotyktu, a first-in-class oral TYK2 inhibitor for treating psoriatic arthritis. This approval not only broadens treatment options for patients but also reinforces the ongoing trend towards developing targeted therapies with novel mechanisms of action. Additionally, Bristol Myers Squibb is gaining momentum with its cereblon E3 ligase modulator (celmod), mezigdomide, achieving statistically significant improvement in progression-free survival among multiple myeloma patients in a Phase 3 trial. This success solidifies BMS's position in hematologic oncology and demonstrates the potential of targeted protein degradation as a therapeutic strategy.The industry is also witnessing significant financial transactions and restructuring efforts. Lonza's decision to sell a majority stake in its capsule business to Lone Star Funds for $3 billion reflects strategic realignments as companies focus on core competencies while leveraging partnerships to optimize business operations.Meanwhile, regulatory scrutiny persists as Democratic lawmakers are investigating 11 pharmaceutical companies regarding their pricing agreements under the previous administration's "most favored nation" clause. This inquiry aims to understand whether these deals have indeed resulted in cost savings for Medicaid, highlighting ongoing concerns about drug pricing transparency and affordability.In another strategic move aimed at bolstering innovation, Regeneron reported promising results from a phase 3 trial conducted by its Chinese partner on a drug mirroring Zepbound's efficacy in obesity treatmenSupport the show

Early STEM experiences impact the innovators of tomorrow. Mike Sherman of Bristol-Myers Squibb shares how the company champions community engagement through events like Super STEM Saturday, offering students across San Diego hands-on science activities and access to diverse role models. From lab demonstrations to interactive experiments, the conversation highlights how real-world STEM exposure can spark curiosity, build confidence, and show students from all backgrounds that a future in science is within reach.Bristol Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases—pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit BMS.com and follow on LinkedIn, X, YouTube, Facebook, and Instagram.

Dr. Pedro Barata and Dr. Kathryn Schmitz discuss evidence-based exercise oncology programs, how to incorporate exercise into cancer care and connect the right patient to the right program, and ultimately build a culture of exercise in oncology. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist and a clinical trialist at the University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also happy to serve as a deputy editor for the ASCO Educational Book. Today, we'll be talking about exercise. We have plenty of evidence that exercise benefits symptoms, improves the quality of life of patients, and actually has been shown to reduce risk of recurrence of cancer but also improve survival. And I think that's increasingly clear as data emerges. Today, I'm delighted to be speaking to Dr. Kathryn Schmitz. She's a leading expert on integrating exercise into cancer care. Dr. Schmitz serves as the deputy director of the University of Pittsburgh Hillman Cancer Center and also a professor of hematology-oncology at University of Pittsburgh Medical School. She's the senior author of a fantastic article in the ASCO Educational Book that's titled "Implementation Science as the Secret Sauce for Integrating Exercise Screening and Triage Pathways in Oncology." She also led a really compelling piece that just got published in JCO titled "If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not" So I'm thrilled to have Dr. Schmitz joining us today and helping us explore evidence-based exercise oncology programs, how to incorporate exercise into cancer care, and also how to connect the right patient to the right program.  So with that, welcome, Dr. Schmitz. Thank you so much for taking the time to chat with us. Dr. Kathryn Schmitz: Thank you for the opportunity. Dr. Pedro Barata: One of the highlights of ASCO last year and practice changing, in my opinion, data out of The New England [Journal of Medicine] is called the CHALLENGE trial. It did provide high level evidence that a structured, supervised exercise program could improve both disease-free survival and overall survival. This is a study in the GI world, but I think it got a lot of attraction and attention beyond the GI world, across solid tumors, really. Could you give us a little brief recap of that trial and what have you seen as being the impact in practices around oncology? Dr. Kathryn Schmitz: So, CHALLENGE was very exciting. Prior to CHALLENGE, there were any number of observational studies that indicated that there was a relationship between being more physically active and reduced recurrence and improved overall survival for colon cancer in particular. You know, notably, in 2006, Jeff Meyerhardt published two papers in the same journal, of the same issue of JCO, showing very, very similar data from two very large studies. And those were studies number five and six in this area. You know, there's a lot of evidence observationally, but we don't generally change clinical practice on the basis of observational data. So, we were all waiting very impatiently for the results of the CHALLENGE trial. And it was very exciting to be in the front row when the results were reported out and to be part of the group with a standing ovation for the authors when it was presented. To summarize, 889 colon cancer patients, stage II and III, were randomized into either a structured exercise program or a health education control comparison group and followed for an average of 7.9 years. And the structured exercise group had a 27% reduced risk of recurrence and a 38% improvement in overall survival. One of the things that's really notable about this is that what we typically expect is that when we go from the observational literature to the clinical trial literature, that we expect effects to go down. We expect to see a larger effect in the observational than in the RCT land, and that did not happen here. We actually see an effect that matches what we've seen in observational literature, which is really, really exciting.  And, you know, one of the reasons why this has been so exciting across not just GI but other cancers is the notable finding of a reduced risk of second primaries. So, they only observed two breast cancer second primaries in the treatment group and 12 in the comparison group. And overall, they reduced the second primaries occurrence, hazard ratio was 0.5, a 50% reduction of second primaries, which is just remarkable. It really got everybody very, very excited. And now the big question, of course, is, all right, how do I do this? How do I make this happen?  The thing to note is that what they did in CHALLENGE is probably not doable in your clinic tomorrow. It's a heavy intervention. The number of touchpoints from staff is extensive, and the amount of time needed from staff for the coaching and supervised exercise is extensive as well. The criteria for getting people into the program required that people go through a series of blood tests and imaging tests that would just simply not be possible for the average community oncologist. So I'm guessing that you're going to ask me some questions about how we do this. Dr. Pedro Barata: Right. That's a fantastic segue. That's exactly right. Walk us through maybe starting by, what does that mean? Dr. Kathryn Schmitz: The first thing to say is I have to go back to the observational literature. And the observational literature shows really compellingly that we have a strong reduction of breast cancer recurrence and mortality from being more physically active, prostate cancer recurrence and mortality, and colon cancer recurrence and mortality. I find it very difficult to believe in this day and age, in our current environment, if you will, that we are ever going to have the equivalent of CHALLENGE for prostate or for breast cancer. There is an ongoing study in prostate that's led by some Australian researchers, but I just don't think that it's likely that we're going to mount something similar for another tumor site. We have tremendous correlative data that indicates that there are a number of biomarkers and biological pathways through which breast, colon, and prostate cancer would be reduced in recurrence if people were more physically active. And so, there is really, from my thinking, very little to state that it would be just a colon cancer effect. And so this is something we probably can enact in more than just the colon cancer community, overall, which is great news, and it makes it easier for us to be able to enact this type of programming. Dr. Pedro Barata: One of the things that comes up perhaps often is, if I were the leader of the cancer center and were to incentivize the different care teams to implement an exercise program at each level: GI team, GU, breast, thoracic, etc. How do we do that? Dr. Kathryn Schmitz: So, I want to give you an analogy. You're a medical oncologist, and you prescribe your patients chemotherapy. Now, just imagine, if you will, what would happen and how likely it would be for your patients to get chemotherapy if there was no chemoinfusion suite. If the chemoinfusion suite disappeared tomorrow and you were to tell your patients, "Go get some chemotherapy," what proportion of those patients do you think would go find all of the equipment necessary and all of the drugs necessary and understand how to dose the chemotherapy for themselves and get that all done? Very few people would do it. So with exercise, why would we be surprised then that our patients don't actually do a whole lot if we just simply tell them to go get some exercise? Exercise is a medicine. It is effective like a medicine. We've shown this through the CHALLENGE trial and many other correlative studies and an ocean of observational data as well. So the question is, how do we build the infrastructure that is necessary in order for your patients to do this? So the very first thing that has to happen is that somebody has to tell the patient to exercise. We currently do not have a culture of exercise in oncology. We do in heart disease. If you ask the average person on the street, "Is exercise good for your heart?" Anybody with an eighth-grade education is going to say, "Yes, of course," because the American Heart Association has done an amazing job telling everybody that exercise is good for your heart. But what has ASCO done, frankly? Can I be that bold? What has ASCO done to tell patients that they should be exercising during and after their cancer treatment? I'm not sure that I know more than a guideline. There is a guideline, and that's great. And the guideline is very helpful, but I'm not sure that patients know that there's a guideline. In fact, I can tell you that patients don't know that there is a guideline. So, you know, making sure that there's a paradigm shift in the country that says exercise is good for patients during and after their cancer treatment is the first step. The second step is getting a medical professional to say something to the patient about the exercise. And I'm very careful with the two words that I just chose: medical professional. I do understand medical oncologists are very busy. I understand that there's a whole lot to say in that 15 minutes when you're with the patient. And so maybe it isn't the medical oncologist. Ideally, it would be, but I get it that there's limited time. So it could be a nurse practitioner, it could be a nurse, there could be a social worker, it could be somebody else on the team that says, "Hey, you know, we want you to do an exercise program. We want to connect you to an exercise program." And then there's what is the program itself? You know, I'm very interested in this happening across the entire country. And so I've been working with the leadership of the Commission on Cancer on the question of, well, how would you do this in community oncology? You know, it's not enough to do it in academic medicine, but how do you do this in community oncology? And you can't expect that every community hospital is going to build a gym for their cancer patients. That is just not reasonable to do. So, we start to try to figure out some phone counseling. Could we give people Fitbits and follow them? Could we use technology to help us? Are there telehealth opportunities for us to do? Are there apps that have been built? In fact, there is a [free] app called Cancer Exercise that's on, you know, all of the platforms and available to patients. So there are programs. I've developed a directory of over 2,000 programs that exist across the country for exercise oncology that patients can find, medical oncologists can find.  So there are a lot of people trying to figure out how best to get the information to medical oncologists and other medical professionals so that they can have an 'easy button' to be able to connect their patients to existing programming so that you don't feel like you have to build a whole new program. Dr. Pedro Barata: If I don't have the resources around me, what would be your advice for the care team or for the providers that might not have that available at their site? Where do they start? Who do they reach out to? Who should they be looking at to get more information on how to set it up? Dr. Kathryn Schmitz: I lead an international consortium called Moving Through Cancer. You can find us at movingthroughcancer.org. That's where you'll find the map of all of the programs across the country and the directory. We actually have a triage tool that sits at the front of the directory that allows people to discern what type of exercise they're safe to do. We do recognize that, you know, the 80-year-old that fell last week doesn't need the same program as the 35-year-old that was playing pickleball the day before diagnosis. So, you know, there are different kinds of programs for people at different levels of acuity. We're happy to be helpful to folks to help them set up programs.  But the number one thing is to really be very aware of the power of saying something about doing exercise, just simply the power of saying, "I want you to be moving." Because frankly, I don't think anybody listening to this would disagree, no one benefits from sitting on the couch all day, no one. No one, no one. It doesn't matter how acute their medical issues are. We get people out of bed. We try to move people even when they're in the hospital. So I think saying something is huge. And then, if you can, applying a triage tool, if you can get something embedded within your clinical flow so that you can understand who it is that needs to go to physical therapy as opposed to who's ready for an exercise program. Those are the two things. So triage and referral is kind of step one. And if you can get that done, the rest will fall into place. Dr. Pedro Barata: This is really powerful message, where one, awareness of the care teams. Number two, bring it up to the patient. And then working on the referral, triage and referral process. That's fantastic. Another aspect that comes up quite a bit is like, "Look, this is great, but we have a system that relies on payers to make things happen, or at least to get them approved." And that can be very different or heterogeneous. The coverage can be different. Sometimes already going through a system programs for interventions, therapeutic interventions, let alone probably the insurance is not going to cover that. Is that true? Is it not true? How do you walk through the different insurance supports, perhaps, depending on where you're practicing? Dr. Kathryn Schmitz: You've just hit on the hot button. I've been working on this issue for about nine years now, trying to figure out using efforts to talk to CMS and see if we can get third party payer coverage going. We were making good progress there, and there was a change of administration and a new focus on "Make America Healthy Again," the MAHA movement. And, you know, CMS is really no longer interested in one-off national coverage determination. They instead, they want to know, "How do we make exercise happen for every American over 65?" And my question is, "Well, wait a minute, cancer patients are not just older patients. There's a lot going on there. They need something special." So I've been working on that. It's been working with accrediting bodies for policy with a little p. Very proud of the work that I've done in collaboration with the National Accreditation Program for Breast Centers, trying to get standards to get exercise referrals for breast patients. And I'm currently holding my breath to see whether the CoC is going to try to make some forward motion in this area as well, crossing all period appendages, waiting for news there. So it's not paid for unless it's done by a physical therapist. And, you know, there's published evidence and I have plenty of evidence from UPMC as well, that people don't really want to go to the physical therapist for this. I'm not saying physical therapists aren't great. Physical therapists are great, and there are people who really need to go to physical therapy, and we try hard to get those patients connected. But for the patients that are ready for something more than physical therapy, we really have an uphill battle to try to figure out what insurers are willing to pay for and what the return on investment is.  One of the challenges with the return on investment is that the timeline, time course for return on investment for American insurers is about one year. And I'll remind you that the time course for return on investment for CHALLENGE was 7.9 years. So we have a mismatch there. So we're trying to figure out if we can produce the evidence to show that there is an improvement in unplanned health care utilization. We have documented that for breast cancer. We're working on it for other cancers. If we can document that it is worthwhile to the insurer to pay for these programs, then I believe that they will pay for them. You know, my conversations are very positive with UPMC, which is a very large insurer and a large health plan. We're slowly working our way towards the middle, where there's a program that they can pay for and a program that is efficacious. That's the puzzle we're trying to solve for right now. Dr. Pedro Barata: This has been wonderful and super helpful. Before we wrap it up, is there anything else you would like to share with our listeners? Dr. Kathryn Schmitz: I want to make sure that your audience is aware that there are a variety of ways that exercise oncology is practiced. The program that most oncologists will be familiar with is LIVESTRONG, which is a program at the YMCA. It's a free program. At one point, there were over 800 locations across the U.S. They have contracted since COVID, probably because of COVID. So they still do exist but imagine, if you will, telling your patients that chemo is only available Tuesdays and Thursdays at 7:00 p.m. It would be difficult for patients to get there and get the chemotherapy. The same thing is true for the LIVESTRONG program. It's a fantastic, fantastic program for people who are able to get there, but that's one option. Another option for patients is there are a variety of online opportunities. I'll call out 2Unstoppable for women's cancers. It's literally the number 2Unstoppable.org. It's a free program available to women with cancer to have live, small group training programs. And they're based in Virginia, but they have programs all over the country. And then finally, I just want to overemphasize the app, the Cancer Exercise app. It's literally called Cancer Exercise in the app store. And that is a super duper easy button, very comprehensive, developed by a nurse scientist, Anna Schwartz. And then there are a variety of books. I wrote a book called Moving Through Cancer. There's a new book out [MyExerciseMedicine for Cancer] by Dr. Rob Newton as well, who's an Australian author. And there are certifications for exercise professionals that folks can look into as well through the American College of Sports Medicine. Dr. Pedro Barata: Dr. Schmitz, this is fantastic. Thank you for sharing those great insights with us. Super, super helpful. Thank you for taking the time. Dr. Kathryn Schmitz: Thank you so much. Dr. Pedro Barata: Thank you to our listeners for your time today. Remember, you'll find links to Dr. Schmitz's fantastic Educational Book as well as the JCO articles in the transcript of this episode. I'll invite all of you to go and read. And we'll also include a link to Dr. Schmitz's book titled Moving Through Cancer: An Exercise and Strength Program for the Fight of Your Life, which empowers patients and caregivers in simple five steps.  So with that, please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you very much for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:           Dr. Pedro Barata    @PBarataMD     Dr. Kathryn Schmitz @fitaftercancer Follow ASCO on social media:           @ASCO on X (formerly Twitter)           ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Pedro Barata:    Stock and Other Ownership Interests: Luminate Medical    Honoraria: UroToday    Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon    Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas    Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck     Dr. Kathryn Schmitz: Patents, Royalties, Other Intellectual Property: Fees from the educational program developed by Dr. Schmitz that is now offered through Klose Training and Consulting.

Adam Haman returns, this time to discuss a recent paper summarizing the performance of leading LLMs in wargames.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.The NewScientist article reporting (inaccurately) on this research paper.BMS ep 467 on the weaknesses of modern game theory.This episode's sponsors, the Scott Horton Academy and The Swan Brothers.The HamanNature substack.Help support the Bob Murphy Show.

Bob continues his commentary on John chapter 3, this time on verses 13 through 17. This includes the famous verse John 3:16, which lays out the recipe for eternal life through belief in Jesus.Mentioned in the Episode and Other Links of Interest:The previous episode in this series, i.e. BMS ep 475, Installment 10: Being Born Again.John Piper on Moses lifting up the serpent.John Piper answers: Does God love the non-elect? Help support the Bob Murphy Show.

As 2026 gets underway, healthcare and life sciences face a year of both promise and pressure, with investment, innovation and equity all in sharp focus. In Part 1 of this year's pharma forecast, four leaders explore where real opportunity lies, from health investment to personalisation and women's health, alongside the key threats that could slow progress.  Speaker bios Dheepa Chari Vice President and Head of Global Scientific Communications, GSK Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered. Emma Charles Senior Vice President of European Markets, BMS Emma oversees BMS operations across 19 countries, bringing extensive global leadership experience spanning Europe, Asia, Latin America and the Middle East. Mary Stutts CEO, Healthcare Businesswomen's Association Mary leads a global organisation advancing the impact of women in healthcare, and is a prominent advocate for inclusive leadership, representative workforces and health equity.

Dr. Pedro Barata and Dr. Ugwuji Maduekwe discuss the evolving treatment landscape in gastroesophageal junction and gastric cancers, including the emergence of organ preservation as a selective therapeutic goal, as well as strategies to mitigate disparities in care. Dr. Maduekwe is the senior author of the article, "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?" in the 2026 ASCO Educational Book. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also the deputy editor of the ASCO Educational Book. Gastric and gastroesophageal cancers are the fifth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Over the last decade, the treatment landscape has evolved tremendously, and today, organ preservation is emerging as an attainable but still selective therapeutic goal. Today, I'm delighted to be speaking with Dr. Ugwuji Maduekwe, an associate professor of surgery and the director of regional therapies in the Division of Surgical Oncology at the Medical College of Wisconsin. Dr. Maduekwe is also the last author of a fantastic paper in the 2026 ASCO Educational Book titled "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Prime Time?" We explore these questions in our conversations today.  Our full disclosures are available in the transcript of this episode as well. Welcome. Thank you for joining us today. Dr. Ugwuji Maduekwe: Thank you, Dr. Barata. I'm really, really glad to be here. Dr. Pedro Barata: There's been a lot of progress in the treatment of gastric and gastroesophageal cancers. But before we actually dive into some of the key take-home points from your paper, can you just walk us through how systemic therapy has emerged and actually allowed you to start thinking about a curative framework and really informing surgery decision-making? Dr. Ugwuji Maduekwe: Great, thank you. I'm really excited to be here and I love this topic because, I'm terrified to think of how long ago it was, but I remember in medical school, one of my formative experiences and why I got so interested in oncology was when the very first trials about imatinib were coming through, right? Looking at the effect, I remember so vividly having a lecture as a first-year or second-year medical student, and the professor saying, "This data about this particular kind of cancer is no longer accurate. They don't need bone marrow transplants anymore, they can just take a pill." And that just sounded insane. And we don't have that yet for GI malignancies. But part of what is the promise of precision oncology has always been to me that framework. That framework we have for people with CML who don't have a bone marrow transplant, they take a pill. For people with GIST. And so when we talk about gastric cancers and gastroesophageal cancers, I think the short answer is that systemic therapy has forced surgeons to rethink what "necessary" really means, right? We have the old age saying, "a chance to cut is a chance to cure." And when I started out, the conversation was simple. We diagnose the cancer, we take it out. Surgery's the default. But what's changed really over the last decade and really over the last five years is that systemic therapy has gotten good enough to do what is probably real curative work before we ever enter the operating room. So now when you see a patient whose tumor has essentially melted away on restaging, the question has to shift, right? It's no longer just, "Can I take this out?" It's "Has the biology already done the heavy lifting? Have we already given them systemic therapy, and can we prove it safely so that maybe we don't have to do what is a relatively morbid procedure?" And that shift is what has opened the door to organ preservation. Surgery doesn't disappear, but it becomes more discretionary. Necessary for the patients who need it, and within systems that can allow us to make sure that we're giving it to the right patients. Dr. Pedro Barata: Right, no, that makes total sense. And going back to the outcomes that you get with these systemic therapies, I mean, big efforts to find effective regimens or cocktails of therapies that allow us to go to what we call "complete response," right? Pathologic complete response, or clinical complete response, or even molecular complete response. We're having these conversations across different tumors, hematologic malignancies as well as solid tumors, right? I certainly have those conversations in the GU arena as well. So, when we think of pathologic CRs for GI malignancies, right? If I were to summarize the data, and please correct me if I'm wrong, because I'm not an expert in this area, the traditional perioperative chemo gives you pCRs, pathologic complete response, in the single digits. But then when you start getting smarter at identifying biologically distinct tumors such as microsatellite instability, for instance, now you start talking about pCRs over 50%. In other words, half of the patients' cancer goes away, it melts down by offering, in this case, immunotherapy as a backbone of that neoadjuvant. But first of all, this shift, right, from going from these traditional, "not smart" chemotherapy approaches to kind of biologically-driven approaches, and how important is pCR in the context of "Do I really need surgery afterwards?" Dr. Ugwuji Maduekwe: That's really the crux of the entire conversation, right? We can't proceed and we wouldn't be able to have the conversation about whether organ preservation is even plausible if we hadn't been seeing these rates of pathologic complete response. If there's no viable tumor left at resection, did surgery add something? Are we sure? The challenge before this was how frequently that happened. And then the next one is, as you've already raised, "Can we figure that out without operating?" In the traditional perioperative chemo era, pathologic complete response was relatively rare, like maybe one in twenty patients. When we go to more modern regimens like FLOT, it got closer to one in six. When you add immunotherapy in recent trials like MATTERHORN, it's nearly triple that rate. And it's worth noting here, I'm a health services-health disparities researcher, so we'll just pause here and note that those all sound great, but these landmark trials have significant representation gaps that limit and should inform how confidently we generalize these findings. But back to what you just said, right, the real inflection point is MSI-high disease where, with neoadjuvant dual-checkpoint blockade, trials like NEONIPIGAS and INFINITY show pCR rates that are approaching 50% to 60%. That's not incremental progress, that's a whole new different biological reality. What does that mean? If we're saying that 50% to 60% of the people we take to the OR at the time of surgery will end up having no viable tumor, man, did we need to do a really big surgery? But the problem right now is the gold standard, I think we would mostly agree, the gold standard is pathologic complete response, and we only know that after surgery. I currently tell my patients, right, because I don't want them to be like, "Wait, we did this whole thing." I'm like, "We're going to do this surgery, and my hope is that we're going to do the surgery and there will be no cancer left in your stomach after we take out your stomach." And they're like, "But we took out my stomach and you're saying it's a good thing that there's no cancer." And yes, right now that is true because it's a measure of the efficacy of their systemic therapy. It's a measure of the biology of the disease. But should we be acting on this non-operatively? To do that, we have to find a surrogate. And the surrogate that we have to figure out is complete clinical response. And that's where we have issues with the stomach. In esophageal cancer, the preSANO protocol, which we'll talk about a little bit, validated a structured clinical response evaluation. People got really high-quality endoscopies with bite-on biopsies. They got endoscopic ultrasounds. They got fine-needle aspirations and PET-CT, and adding all of those things together, the miss rate for substantial residual disease was about 10% to 15%. That's a number we can work with. In the stomach, it's a lot more difficult anatomically just given the shape of people's stomachs. There's fibrosis, there's ulceration. A fair number of stomach and GEJ cancers have diffuse histology which makes it difficult to localize and they also have submucosal spread. Those all conceal residual disease. I had a recent case where I scoped the patient during the case, and this person had had a 4 cm ulcer prior to surgery, and I scoped and there was nothing visible. And I was elated. And on the final pathology they had a 7 cm tumor still in place. It was just all submucosal. That's the problem. I'm not a gastroenterologist, but I would have said this was a great clinical response, but because it's gastric, there was a fair amount of submucosal disease that was still there. And our imaging loses accuracy after treatment. So the gap between what looks clean clinically and what's actually there pathologically remains very wide. So I think that's why we're trying to figure it out and make it cleaner. And outside of biomarker-selected settings like MSI-high disease, in general, I'm going to skip to the end and our upshot for the paper, which is that organ preservation, I would say for gastric cancer particularly, should remain investigational. I think we're at the point where the biology is increasingly favorable, but our means of measurement is not there yet. Dr. Pedro Barata: Gotcha. So, this is a perfect segue because you did mention the SANO, just to spell it out, "Surgery As Needed for Oesophageal" trial, so SANO, perfect, I love the abbreviation. It's really catchy. It's fantastic, it's actually a well-put-together perspective effort or program applying to patients. And can you tell us how was that put together and how does that work out for patients? Dr. Ugwuji Maduekwe: Yeah, I think for those of us in the GI space, we have SANO and then we also have the OPRA for rectum. SANO for the upper GI is what takes organ preservation from theory to something that's clinically credible. The trial asked a very simple question. If a patient with a GEJ adenocarcinoma or esophageal adenocarcinoma achieved what was felt to be a clinical complete response after chemoradiation, would they actually benefit from immediate surgery? And the question was, "Can you safely observe?" And the answer was 'yes'. You could safely observe, but only if you do it right. And what does that mean? At two years, survival with active surveillance was not inferior to those who received an immediate esophagectomy. And those patients had a better early quality of life. Makes sense, right? Your quality of life with an esophagectomy versus not is going to be different. That matters a lot when you consider what the long-term metabolic and functional consequences of an esophagectomy are. The weight loss, nutritional deficiencies that can persist for years. But SANO worked because it was very, very disciplined and not permissive. You mentioned rigor. They were very elegant in their approach and there was a fair amount of rigor. So there were two main principles. The first was that surveillance was front-loaded and intentional. So they had endoscopies with biopsies and imaging every three to four months in the first year and then they progressively spaced it out with explicit criteria for what constituted failure. And then salvage surgery was pre-planned. So, the return-to-surgery pathway was already rehearsed ahead of time. If disease reappeared, take the patient to the OR within weeks. Not sit, figure out what that means, think about it a little bit and debate next steps. They were very clear about what the plan was going to be. So they've given us this blueprint for, like, watching people safely. I think what's remarkable is that if you don't do that, if you don't have that infrastructure, then organ preservation isn't really careful. It's really hopeful. And that's what I really liked about the SANO trial, aside from, I agree, the name is pretty cool. Dr. Pedro Barata: Yeah, no, that's a fantastic point. And that description is spot on. I am thinking as we go through this, where can this be adopted, right? Because, not surprisingly, patients are telling you they're doing a lot better, right, when you don't get the esophagus out or the stomach out. I mean, that makes total sense. So the question is, you know, how do you see those issues related to the logistics, right? Getting the multi-disciplinary team, getting the different assessments of CR. I guess PETs, a lot of people are getting access to imaging these days. How close do you think this is, this kind of program, to be implemented? And maybe I would assume it might need to be validated in different settings, right, including the community. How close or how far do you think you see that being applied out there versus continuing to be a niche program, watch and wait program, in dedicated academic centers? Dr. Ugwuji Maduekwe: I love this question. So I said at the top of this, I'm a health equity/health disparities researcher, and this is where I worry the most. I love the science of this. I'm really excited about the science. I'm very optimistic. I don't think this is a question of "if," I think it's a question of "when." We are going to get to a point where these conversations will be very, very reasonable and will be options. One of the things I worry about is: who is it going to be an option for? Organ preservation is not just a treatment choice, and I think what you're pointing out very rightly is it's a systems-level intervention. Look at what we just said for SANO. Someone needs to be able to do advanced endoscopy, get the patients back. We have to have the time and space to come back every three to four months. We have to do molecular testing. There needs to be multi-disciplinary review. There needs to be intensive surveillance, and you need to have rapid access to salvage surgery. Where is that infrastructure? In this country, it's mostly in academic centers. I think about the panel we had at ASCO GI, which was fantastic. And as we were having the conversation, you know, we set it up as a debate. So folks were debating either pro-surveillance or pro-surgery. But both groups, both people, were presenting outcomes based on their centers. And it was folks who were fantastic. Dr. Molena, for example, from Memorial Sloan Kettering was talking about their outcomes in esophagectomies [during our session at GI26], but they do hundreds of these cases there per year. What's the reality in this country? 70% to 80% to 90%, depending on which data you look at, of the gastrectomies in the United States occur at low-volume hospitals. Most of the patients at those hospitals are disproportionately uninsured or on government insurance, have lower income and from racial and ethnic minority groups. So if we diffuse organ preservations without the system to support it, we're going to create a two-tiered system of care where whether you have the ability to preserve your organs, to preserve bodily integrity, depends on where you live and where you're treated. The other piece of this is the biomarker testing gap. One of the things that, as you pointed out at the beginning, that's really exciting is for MSI-high tumors. Those are the patients that are most likely to benefit from immunotherapy-based organ preservation. But here's the problem. If the patient isn't tested at time of initial diagnosis before they ever see me as a surgeon, the door to organ preservation is closed before it's ever open. And testing access remains very inconsistent across academic networks. And then there's the financial toxicity piece where, for gastrectomy, pancreatectomy, I do peritoneal malignancies, more than half of those patients experience significant financial toxicity related to their cancer treatment. We're now proposing adding at least two years, that's the preliminary information, right? It's probably going to be longer. At least a couple of years of surveillance visits, repeated endoscopies, immunotherapy costs. How are we going to support patients through that? We're going to have to think about setting up navigation support, geographic solutions, what financial counseling looks like. My patient for clinic yesterday was driving to see me, and they were talking about how they were sliding because it was snowing. And they were sliding for the entire three-hour drive down here. Are we going to tell people like that that they need to drive down to, right, I work at a high-volume center, they're going to need to come here every three months, come rain or snow, to get scoped as opposed to the one-time having a surgery and not needing to have the scopes as frequently? My concern, like I said, I'm an optimist, I think it is going to work. I think we're going to figure out how to make it work. I'm worried about whether when we deploy it, we widen the already existing disparities. Dr. Pedro Barata: Gotcha, and that's a fantastic summary. And as I'm thinking also of what we've been talking in other solid tumors, which one of the following do you think is going to evolve first? So we are starting to use more MRD-based assays, which are based on blood test, whether it's a tumor-informed ctDNA or non-informed. We are also trying to get around or trying to get more information response to systemic therapies out of RNA-seq through gene expression signatures, or development of novel therapeutics which also can help you there. Which one of these areas you think you're going to help this SANO-like approach move forward, or you actually think it's actually all of the above, which makes it even more complicated perhaps? Dr. Ugwuji Maduekwe: I think it's going to be all of the above for a couple of reasons. I would say if I had to pick just one right now, I think ctDNA is probably the most promising and potentially the missing piece that can help us close the gap between clinical and pathologic response. If you achieve clinical complete response and your ctDNA is negative, so you have clinical and molecular evidence of clearance, maybe that's a low-risk patient for surveillance. If you have clinical complete response but your ctDNA remains positive, I would say you have occult molecular disease and we probably need intensified therapy, closer monitoring, not observation. I think the INFINITY trial is already incorporating ctDNA into its algorithm, so we'll know. I don't think we're at the point where it alone can drive surgical decisions. I think it's going to be a good complement to clinical response evaluation, not a replacement. The issue of where I think it's probably going to be multi-dimensional is the evidence base: who are we testing? Like, what is the diversity, what is the ancestral diversity of these databases that we're using for all of these tests? How do we know that ctDNA levels and RNA-seq expression arrays are the same across different ancestral groups, across different disease types? So I think it's probably going to be an amalgam and we're going to have to figure out some sort of algorithm to help us define it based on the patient characteristics. Like, I think it's probably different, some of this stuff is going to be a little bit different depending on where in the stomach the cancer is. And it's going to be a little bit more difficult to figure out if you have a complete clinical response in the antrum and closer to the pylorus, for example. That might be a little bit more difficult. So maybe the threshold for defining what a clinical complete response needs to be is higher because the therapeutic approach there is not quite as onerous as for something at the GE-junction. Dr. Pedro Barata: Wonderful. And I'm sure AI, whether it's digitization of the pathology from the biopsies and putting all this together, probably might play a role as well in the future.  Dr. Maduekwe, it's been fantastic. Thank you so much for sharing your insights with us and also congrats again for the really well-done review published.  For our listeners, thank you for staying with us. Thank you for your time. We will post a link to this fantastic article we discussed today in the transcript of this episode. And of course, please join us again next month on the By the Book Podcast for more insights on key advances and innovations that are shaping modern oncology. Thank you, everyone. Dr. Ugwuji Maduekwe: Thank you. Thank you for having me. Watch the ASCO GI26 session: Organ Preservation for Gastroesophageal and Gastric Cancers: Ready for Primetime? Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ugwuji Maduekwe @umaduekwemd Follow ASCO on social media:          @ASCO on X (formerly Twitter)          ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ugwuji Maduekwe: Leadership: Medica Health Research Funding: Cigna    

Chapter 129This week Queen tells us about her going to a party with her Dom and we see videos of their BDSM session during the party. Then we discuss all that is going on wit porn and these platforms. Now it's time to podcast and we start with us reacting to two videos from Conversations Tonight. The first one was a lady who had two brain surgeries and she is complaining about her husband not being romantic after he nursed her back to good health. The 2nd one was a lady asking about getting out of and over a lesbian relationship. We unpack both and we discuss the three types of cheater for both men and women. Then , we discuss a lady who has both of her BMs names tatted on her but the real tea is her "I'm His Cum Bucket " Tattoo. Then we unpack bad roommates and more.Watch the Full Episode as a Premium Smoker in The Premium Smoke Room On Loyalfanshttps://tinylf.com/qEOiWRZkp4GCyU9

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the industry landscape, from regulatory advancements to scientific breakthroughs and strategic business maneuvers.Kicking off with a significant regulatory update, the FDA's Rare Pediatric Disease Voucher Program has been rejuvenated through a newly signed government funding bill. This initiative is designed to expedite the development of treatments for rare pediatric diseases, offering crucial incentives to companies targeting this critical healthcare segment. By reauthorizing this program, there's an expectation of stimulating innovation and potentially bringing more treatments to market for conditions with limited existing therapies. This move underscores a broader commitment to addressing unmet medical needs through incentivized innovation.Turning to corporate developments, Eli Lilly is anticipating substantial growth in revenue despite facing pricing pressures on its key products, Mounjaro and Zepbound. The company projects revenues between $80 billion and $83 billion for 2026, marking a 25% increase from 2025 at the midpoint. This growth is attributed to strong product performance and strategic maneuvers within their pipeline. Eli Lilly has also made strategic decisions by optimizing its pipeline through dropping three clinical-stage drugs, including a gene therapy acquired via Prevail Therapeutics. This move points towards Lilly's focus on concentrating efforts on more promising candidates within their expansive pipeline. Additionally, Eli Lilly is expanding its GLP-1 franchise beyond metabolic diseases into immunology and inflammation with ongoing clinical trials in conditions such as asthma, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This strategic expansion could lead to novel therapeutic options for chronic inflammatory diseases.Similarly, Bristol Myers Squibb is focusing on new growth drivers amid declining sales of legacy drugs. With $48.2 billion in revenue projected for 2025 largely stemming from newer products, BMS is strategically repositioning itself to maintain momentum amidst market changes.Novartis faces its largest patent expiry challenge but remains optimistic about its trajectory. CEO Vas Narasimhan suggests robust strategies are in place to counteract these patent expiries, indicating a strong focus on innovation and strategic planning to navigate these hurdles. Novartis is also refining its oncology strategy by cutting early-stage cancer candidates while adding new ones focused on promising therapeutics—a broader trend of adopting data-driven approaches to streamline drug development pipelines.Meanwhile, AbbVie continues its stronghold in the inflammatory bowel disease market with its blockbuster immunology drugs Skyrizi and Rinvoq. These products significantly contribute to AbbVie's $61.1 billion revenue, highlighting their commitment to maintaining leadership in immunology despite competitive pressures from rivals like Johnson & Johnson.Astellas has exceeded expectations with its cancer drug Vyloy overcoming a trial setback to quadruple sales in the third quarter fiscal year 2025 results. This success underscores the resilience and potential of innovative oncology treatments even when faced with clinical challenges.In financial markets, Veradermics successfully raised $256 million through its IPO, signaling strong investor interest in biotech firms with promising dermatological applications. Concurrently, Eikon Therapeutics marked the largest biotech IPO since 2024 with a $381 million listing on Nasdaq, reflecting renewed investor confidence in biotech ventures. Industry trends indicate a resurgence of interest in public markets exemplified by Eikon Therapeutics' upsized IPO alongside Veradermics' successful Support the show

If you work across time zones, borders, and cultures, this is the show for you. This is your host Leonardo, welcome to The International Business Podcast. AI can now summarise almost anything in seconds. That's powerful, but it makes it easy to stay at the surface. We get headlines, bullet points, "3 key takeaways", and move on. What's lost is context, nuance, and understanding that changes how professionals think and decide in international business. With this new format, host Leonardo Marra pushes in the opposite direction. Instead of a quick AI overview, he built a long‑form deep dive into Japan after 1945: from World War II defeat to economic miracle, bubble, stagnation, and today's super‑aging, innovation‑driven society.Part 1 traces Japan's path from post‑war devastation through U.S. occupation, state‑guided capitalism, keiretsu networks, export‑led growth, oil shocks, the 1980s bubble, and the "lost decades." It links policy, institutions, and social change to Japan's rise and current challenges.Part 2 shifts to practical insights. Guests who live and work in and around Japan share how firms make decisions, how kaizen and relationships function, how demographics reshape strategy, and what foreign executives consistently misunderstand about the Japanese market.--------⁠Join Leonardo on Patreon for Podcast Archive and Bonus episodes (100+ episodes). ⁠--------With guests:Massimiliano Colonna – Director of Communications, Brookings Institution Governance Studies. MPhil in Modern Japanese Studies from Oxford's Nissan Institute, where he researched the internet's role in Japan's political debate.Waka Someno – CEO of YOUNEEDS Co., Ltd. and SOMENO-YA (Tokyo/Osaka). Provides sales, marketing, and legal support for international companies entering Japan. Over 15 years in B2B sales, DX solutions, and market-entry advisory.Jason Durkee – President, Idea Development (Tokyo); co-founder, Practical Training Transfer. 25+ years helping businesspeople innovate, communicate across cultures, and transfer learning to results. CPTD, ATD Japan director, serves 130+ clients annually across Asia.Neal Jansen – Director, Asia Office, Arkansas Economic Development Commission. CEcD with 20+ years in FDI, trade, and workforce development. Fluent in Japanese, builds long-term partnerships between Arkansas and Asian companies.Brett Jason Lee – Learning and performance professional specializing in Asia Pacific; ICF Professional Certified Coach (PCC). Designs learning solutions focused on behavior change, capability building, and cultural context for Japan and the region.Shaun Rein – Founder & Managing Director, China Market Research Group (Shanghai). Author of five bestselling books on China's economy. Works with Fortune 500s, PE firms, and heads of state. Regular contributor to WSJ, FT, NYT, CNBC, CNN, Bloomberg. Harvard MA.Tom Roberts – Founder, Cranberry Leadership International. "The Expat Whisperer." Former Head of Japan - Neurology at UCB (200 people, ~$1B P&L) and MD/President UCB Korea. Forbes Coaches Council member, helps C-Suite leaders navigate cross-border challenges.Jeff O'Dea – Communication Specialist, Inspiringbiz (Tokyo). Since 2010, helps Japanese professionals communicate effectively in English for global meetings. Clients include BMS, Novartis, MSD, Chugai, Merck, UCB, Softbank.Kelvin Ro – Founder, Kagi Career LLC (Tokyo, 15+ years). Coaches non-Japanese professionals on landing jobs in Japan. Author of Three Ways to Land Your First Job in Japan; ranked #2 non-Japanese LinkedIn creator in Japan (Dec 2024).-----If you work across time zones, borders, and cultures, come on the show to share your story. ⁠Connect with the host Leonardo Marra.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory challenges, and strategic investments that are shaping the future of healthcare.Let's begin with Moderna's recent decision to halt its late-stage vaccine trials, a move reflective of a broader trend of vaccine hesitancy in the United States. Moderna's CEO Stéphane Bancel pointed to shifts in government policy and an increasing public skepticism towards vaccines as pivotal reasons for this decision. This development signals a potential slowdown in vaccine research and development investments across the industry. The implications are profound, as vaccine hesitancy could impact public health initiatives and the readiness to tackle future pandemics.In parallel developments, Sanofi is navigating its own set of challenges with its eczema treatment. Despite plans to file for FDA approval for its OX40 blocker following the Phase III COAST 2 trial, results were mixed, echoing earlier data that analysts found underwhelming. This situation highlights the inherent uncertainties in drug development and raises questions about the treatment's potential market success. As Sanofi persists, the broader industry is reminded of the complexities involved in bringing new therapies to market, particularly in dermatology where unmet needs remain significant.Meanwhile, Chinese biotech firm Corxel has secured an impressive $287 million in Series D1 funding to push forward its oral GLP-1 therapy, CX11. This funding will support its mid-stage development in the US and preparations for Phase III studies. The investment underscores a robust interest in GLP-1 therapies known for their efficacy in treating type 2 diabetes and obesity. The competitive landscape for these therapies is heating up, with major players vying for market dominance through novel delivery mechanisms and enhanced patient outcomes. Notably, Novo Nordisk's oral Wegovy is advancing while Eli Lilly's Orforglipron faces delays, highlighting the strategic importance of timely development and market entry in capturing lucrative opportunities within this therapeutic area.On the regulatory front, a notable legislative challenge has emerged with the failure to reauthorize the FDA's rare pediatric disease priority review voucher program for 2024. Advocates are calling for its reinstatement given its critical role in incentivizing the development of rare disease treatments through expedited review processes. Such regulatory changes underscore the delicate balance between encouraging innovation and ensuring rigorous standards, a dynamic that continuously shapes R&D strategies within the industry.In oncology, Bristol Myers Squibb is making headlines with an $850 million investment in Janux Therapeutics' tumor-activated drugs. This significant investment reaffirms BMS's commitment to pioneering cancer therapies that promise better patient outcomes through innovative mechanisms of action. The focus on oncology reflects a broader industry trend towards precision medicine and targeted treatments aimed at improving efficacy while minimizing side effects.As we pivot to manufacturing developments, Lotte Biologics is expanding its capabilities with plans to launch its Syracuse ADC hub by 2026. This expansion aligns with global efforts to enhance manufacturing quality and capacity, crucial factors as biopharmaceuticals become more complex and demand increases.Turning our attention to financial achievements within the industry, Samsung Biologics has reached a historic milestone by becoming the first Korean biopharmaceutical company to surpass a profit threshold of 2 trillion won ($1.36 billion). This accomplishment spotlights the growing influence of contract manufacturing organizations (CMOs) like Samsung BiologicsSupport the show

Para entender lo que las marcas no te explican. Porque el automóvil está cambiando radicalmente. Nuestra querida jerga de cilindradas, compresión y árboles de levas está siendo sustituida por un nuevo diccionario lleno de siglas que, admitámoslo, muchas veces parecen diseñadas para confundirnos. Hoy no vamos a debatir si el eléctrico es el futuro o no; hoy vamos a diseccionar la tecnología con "ingeniería a tu alcance" para que, cuando leas una ficha técnica, entiendas de verdad qué te están vendiendo. Aquí tienes los pilares fundamentales para entender un coche eléctrico moderno: 1. kW vs. kWh La gran confusión Es la base de todo y donde más gente se pierde. -kW (Kilovatios): Es la POTENCIA. Equivale a lo que antes llamábamos caballos (CV). Para pasar de kW a CV solo multiplica por 1,36. Representa la fuerza del motor o la velocidad de carga. -kWh (Kilovatios-hora): Es la ENERGÍA. Es la capacidad de la batería, equivalente a los litros del depósito de gasolina. Piensa en un cubo de agua: los kWh son el tamaño del cubo (cuánta agua cabe) y los kW son el grosor de la manguera. Tener muchos kWh (batería grande) no garantiza cargar rápido si tu sistema de carga (kW) es lento. 2. El Corazón: Motores Síncronos vs. Asíncronos No todos los "motores de 200 CV" son iguales. Existen dos grandes familias: -Síncronos de Imanes Permanentes (PSM): El rotor gira a la misma velocidad que el campo magnético. Son los reyes de la eficiencia (más del 90%) y ultra precisos, ideales para ciudad. La desventaja es que son caros y pueden generar resistencia al rodar por inercia si no se gestionan bien. -Asíncronos o de Inducción (ASM): El rotor gira algo más lento que el campo magnético. Son robustos y más baratos (sin imanes de tierras raras). Su gran ventaja es que no ofrecen resistencia cuando no se usan, permitiendo ir "a vela" en autopista sin consumo. Muchos coches de tracción total inteligentes usan un motor síncrono en un eje para el día a día y un asíncrono en el otro que solo "despierta" al pisar a fondo. 3. La Química de la Batería Exige saber qué química lleva tu coche, porque determina su vida útil y uso. -NCM (Níquel-Cobalto-Manganeso) / NCA: Son las baterías de alto rendimiento. Ofrecen mucha densidad energética (mucha autonomía en poco peso), ideales para viajes largos y deportivos. Sin embargo, son más caras, inestables térmicamente y sufren si se cargan siempre al 100%. -LFP (Litio-Ferrofosfato): Son las baterías que están democratizando el eléctrico. Son rocas: muy seguras, difícilmente arden, baratas y con una vida útil larguísima (+2.000 ciclos). A diferencia de las NCM, a las LFP debes cargarlas al 100% frecuentemente para calibrar su gestión. Su contra es que pesan más y sufren más con el frío extremo. 4. Voltios y Carga: 400V vs 800V La mayoría de eléctricos funcionan a 400 Voltios, pero los más sofisticados saltan a 800 Voltios. ¿La diferencia? En un sistema de 800V, la electricidad se empuja con más presión (voltaje) y menos intensidad, lo que reduce el calor y permite usar cables más finos. Esto se traduce en cargas ultrarrápidas consistentes, recuperando del 10 al 80% en apenas 18 minutos. Glosario Básico para no perderse: -BMS (Battery Management System): El director de orquesta. Controla temperatura y voltaje de cada celda. Un buen BMS define si tu batería durará 10 años o 3. -Curva de Carga: Olvida el "pico de potencia". Lo importante es la potencia media. Muchos coches tienen un pico alto que cae a los 5 minutos. -Frenada Regenerativa: El motor se vuelve generador. Úsala al máximo en ciudad (One Pedal) y minimízala en autopista para aprovechar la inercia. -Frunk: Maletero delantero, ideal para cables sucios. -WLTP vs. Realidad: Para saber la autonomía real en autopista a 120 km/h, resta un 25-30% a la cifra oficial WLTP. El enemigo es la aerodinámica. -Vampire Drain: El consumo fantasma de tu coche parado (sistemas de vigilancia, conectividad, etc.). Entender un coche eléctrico requiere cambiar el chip: dejamos de mirar cilindros para mirar celdas. Si es para ciudad, busca LFP y eficiencia; si es para viajar, busca aerodinámica, NCM y 800V. La información es poder.

Live Work with Madeleine I'm Helpless! Part 2 of 3 Today, we are pleased to present the exciting conclusion of our work with Madeleine, a loving mother who fears that her eldest daughter might be in mortal danger during her year abroad. Last week, you heard about the T = Testing and E = Empathy phase of the live work with Madeleine, a mother feeling intense panic and helplessness and inadequacy because she fears that her daughter could be in grave danger of abduction and worse. This week, we will focus on A = Paradoxical Agenda Setting, using the Miracle Cure Question, Magic Button, Positive Reframing, and Magic Dial to see if we can melt away her resistance to change. You can see the Emotions table of the Daily Mood Log Madeleine during the Magic Dial portion of the session if you Click Here As you can see, she wanted to reduce her negative feelings somewhat, but thought she still wanted to keep them fairly elevated, since she still sensed that her daughter might be in real danger, and clearly did not want to abandon her. This is one of the significant refinements in TEAM CBT. First, we want to bring the patient's resistance to full conscious awareness. Second, we want patients to full grasp that their negative thoughts and feelings do NOT result from some "defect" or "mental disorder," but rather from what is most beautiful and awesome about them as human beings. After the Magic Button, David and Jill went on to the final, M = Methods portion of the TEAM session, using tools such as Identify and Explain the Distortions, the Double Standard Technique, and the Externalization of Voices, with the Acceptance Paradox, the Self-Defense Paradigm, and the CAT (Counter-Attack Technique). We will, of course, do numerous role reversals to see if we can get Madeleine to a "huge" victory over her many distorted thoughts. You can see the Daily Mood Log Madeleine prepared at the end of the session if you Click Here As you can see, the reductions in negative feelings were dramatic, but in several areas (anxiety, inadequacy, frustration and anger), Madeleine's negative feelings were still minimally elevated. That is one of the reasons we decided to schedule an additional session together several weeks later to see if we could intensify Madeleine's responses to her negative thoughts, and hopefully due some Cognitive Flooding to complete her "treatment." At the end of these show notes, you will find an email from Madeleine after the session that includes her end-of-session scores on the BMS and EOTS. You will also see comments submitted by many participants who attended the webinar live. This email below from Madeleine following the session shows her end of session scores on the Brief Mood Survey as well as the Evaluation of Therapy Session at the end of her session with Jill and David. Hi David, Yes, here are my BMS & ETS score totals after the extended session. Please let me know if you have any questions. A relapse prevention session would be nice; however, I hesitate to accept your offer as you all are so busy. Please know that I am practicing the PTs and keeping the NTs in check for now. Thank you again a million times over

Bob covers John 3: 1-12, where Jesus tells Nicodemus that he must be born again to see the kingdom of God.Mentioned in the Episode and Other Links of Interest:The previous episode in this series, i.e. BMS ep. 396, Installment 9: Cleansing the Temple.Help support the Bob Murphy Show.

Live Work with Madeleine I'm Helpless! Part 1 of 3 Today, we are pleased to present one of our favorite podcast topics—live work with a real human being who is suffering. We will be working with Madeleine, a woman who read a disturbing article while at the hairdresser and freaked out, sensing that one of her daughters might be in mortal danger. This live and unedited session was first presented as part of a free webinar on September 11, 2025. There was no preparation or role-playing—everything was absolutely real and spontaneous, exactly as it evolved in real time. We present Part 1 as our final Feeling Good Podcast for our 2025 season. This is our most powerful and popular type of podcast, and we hope you enjoy it. We also give a big thanks to our courageous "patient," Madeleine. My co-therapist will be Dr. Jill Levitt, a clinical psychologist and Director of Training at the Feeling Good Institute in Mountain View, California. Jill and I greatly enjoy working together as co-therapists when we teach and we typically see our "patient" for an extended, two-hour session. We find that this is the most effective format for teaching, and that way, we can frequently complete a course of therapy in a single session. However, you do not need more than one therapist to do effective TEAM CBT, and you can do it in conventional 50 minute sessions as well. But often, you can do vastly more in a double session. We will not be engaged in an ongoing therapeutic relationship with Madeleine. When we work with therapists, they are doing personal work as a part of their training. We feel that this experience is vital for every therapist who hopes to do world-class TEAM CBT with their own patients / clients. More than 2,000 individuals registered for this workshop. Although the workshop was open to everyone, only 13% of the participants identified as general public, while 87% identified as mental health professionals.  In Part 1, which we present today, we focused on T = Testing and E = Empathy phases of the TEAM session. In Part 2, which you will hear next week, we will focus on A = Paradoxical Agenda Setting and M = Methods. We will also show you the changes in her scores on the Daily Mood Log (DML) and Brief Mood Survey (BMS) from the start to the end of the session, as well as Madeleine's scores on the Evaluation of Therapy Session (EOTS) at the end, including what she liked the most and least about the session. That way, we can see clearly how much improvement there was (or wasn't) during the session, and how Jill and I did in terms of empathy, helpfulness, and other scales that evaluate the patient's view of the session. In Part 3, which you will hear in two weeks, we did more Externalization of Voices along with Cognitive Exposure, since we had some loose ends we wanted to tie up before completing our work with Madeleine. This follow-up session occurred many weeks after the initial session at the workshop, and will also serve as a follow-up to see how Madeleine did in the days following the live work. Part 1 of 3 Our "patient," Madeleine, is a courageous woman who experienced sheer panic after being triggered at the hair salon while reading an article about a young woman who was abducted. Since Madeleine's oldest daughter's is away at college, taking a year abroad, Madeleine realized she could not protect her from predators and freaked out, thinking about all the horrible things that could happen to her. In addition, Madeleine had many self-critical thoughts about ways she thought she had failed her daughter when her daughter was growing up, and worried about her daughter's judgement: She hasn't always made the best decisions about guys she's gone out with, and she's shared everything with me. She says, 'Don't worry mom. I've learned from this.'" At the start of the session, we reviewed Madeleine's scores on the Brief Mood Survey (BMS). This indicated only minimal depression (5/20), with no suicidal urges or anger, but her anxiety was still extremely elevated (18/20). In addition, her Positive Feelings score was only 20 out of 40, with 0 meaning no positive feelings at all, and 40 being the highest possible feelings. However, her Relationship Satisfaction score with her husband was 25 out of 30, which indicates strong satisfaction, with just a little room for improvement. We will ask Madeleine to complete the BMS again, along with the EOTS, so we can see precisely what changed, and by how much, during the session. Our goal, of course, with TEAM CBT, is nearly always to cause a near-complete, or complete, elimination of symptoms during a single, extended therapy session. In addition, we want every patient to have a crystal clear understanding of how and why they got upset, along with how to use the tools that were the most helpful to them in the session. That way, they'll be armed to deal with future relapses, which are inevitable for all human beings. And here's the big point. Our goal in sharing this session with you is so you can feel inspired, and see that rapid recovery really IS possible. And if you're a therapist, we hope that you will feel motivated to learn TEAM CBT so you can significantly improve your outcomes with your own patients. You can see the Daily Mood Log Madeleine prepared just prior to the session if you Click Here The upsetting situation was reading the article about the young abducted woman in the hair salon. On the Emotions table  she indicated that she was feeling sad, down, and unhappy (85%), anxious, frightened and panicky (100%), inadequate (100%), frustrated (90%), and angry and upset (100%). These extremely high ratings tells us that Madeleine's negative feelings were about as intense as a human being can experience. Although your life is undoubtedly very different from Madeleine's, perhaps you, too, have felt panic and helplessness when you thought the life of a loved one might be in danger. Madeleine generated several additional negative Thoughts during the empathy phase of the session, including, I'm totally responsible for how she's turned out. 95% I was not present enough for her. 95% She may not trust that I'm there for her. 60% She's anxious and insecure and a people-pleasure, and she's also perfectionistic, and it's all my fault. 75% I should have been more sensitive when she was growing up. I expected too much. 100% Again, if you're a parent, you may have had similar negative thoughts about your own parenting. I know that I have! During the Empathy phase, Madeleine described her horrors when reading the article at the hairdresser's, with thoughts of Natalie Hollaway's brutal murder as well as other women who were abducted and murdered. Madeleine explained that she and her husband both married late, and felt somewhat insecure as parents: "It wasn't easy having children late in life. . . .  When our first baby was born, the milk was not coming down. My daughter would look deep into my eyes, and I had the thought, 'I'm letting my daughter down.'" She said she had a rough time when she was growing up and her parents got divorced: "My heart was broken, and I had to learn to be strong. I had to learn not to let so much emotion through. I had to learn how to keep guys at arm's length. I had to protect myself from getting hurt." She said that wanted her daughters to grow up being strong and independent, but as she reflects back, she thinks she may have failed them and not provided enough warmth and support. Our goal during E = Empathy is not to help or even try change anything, but simply to go with our patients to the gates of hell, so they can vent, cry, and express their deepest and most private feelings. At the end of the Empathy portion of the session, we asked Madeleine to grade us on the three key elements of empathy, using letter grades: How accurately did we understand how you were thinking? How accurately did we understand how you were feeling inside? To what extent did we convey the spirit of trust, warmth, and acceptance? She gave us 3 A's, indicating it was time to move on to A = Paradoxical Agenda Setting, which you will hear next week. We will want to find out what Madeleine might want help with. We will also try to melt away her resistance to change using the Miracle Cure Question, the Magic Button, Positive Reframing, and the Magic Dial.    Why would we anticipate resistance? After all, Madeleine is asking for help. But remember, the desire for change cannot always be take for granted in anyone. Nearly all of us have mixed feelings about change. After all, a loving and concerned mother might NOT want to stop worrying about a beloved daughter who seems to be in grave danger! But if you deal with this resistance in a compassionate way, you may open the door to the possibility of rapid healing when you come to the M = Methods portion of the session. We can check it out at the exciting conclusion of the work with Madeleine next week!

It's the Weekend Baby!Close the laptop, answer the last email, and tell the boss to…. Well, you may want to return to a job on Monday but until then, it's your time to express yourself through music and dance. This collection of songs tells that story of short-term emancipation of those structured roles. So let loose, have fun, and have something to talk about on Monday.For now – you're Livin' for the Weekend with BMS!This episode includes Cherrelle, The S.O.S Band, The Gap Band, Montell Jordan, K-OS and many others.Let's take this ride together and remember when music was Music!1. SATURDAY LOVE/CHERRELLE2. STOMP/BROTHER'S JOHNSON3. PARTY TRAIN/GAP BAND4. NIGHT CRUISING/The Bar-Kays5. HERE I GO AGAIN (ANOTHER WEEKEND)/KWICK6. LOOKOUT WEEKEND/DEBBIE DEB7. WEEKEND/FIBRE FOUNDATION8. NO WORRIES/NOEL GOURDIN (HILL ST. SOUL)9. GOOD TIME/CHARLIE WILSON10. THIS IS HOW WE DO IT /MONTELL JORDAN11. SATURDAY/DE LA SOUL12. THE CLUB/SIR PIERS13. LOOKIN' FOR LOVE/FAT LARRY'S BAND14. SUNDAY MORNING/K-OS15. BACKYARD PARTY/R. KELLY16. WEEKEND GIRL/S.O.S. BAND17. GOOD TIMES/CHIC

Economist Steve Landsburg gives a presentation based on his new book, which uses intuitive analogies to really explain the slowdown in time and other odd implications of the theory of special relativity.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.Order Steve Landsburg's books.A great "Mechanical Universe" episode showing Lorentz transformations with intuitive animations.BMS interview with Landsburg on the math genius Grothendieck.Help support the Bob Murphy Show.

Keith Smith is founder of the Surgery Center of Oklahoma. He returns to the podcast to summarize his recent testimony on medical costs.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.The CSPAN video of the testimony.The Surgery Center of Oklahoma. The Free Market Medical Association (FMMA). Matt Ohrt's appearance on the BMS.The Tuttle Twins Academy (with Black Friday discount).Help support the Bob Murphy Show.

Hello to our lovely coven, happy Wednesday! Katie and Dayna are joined by the coven's favorite boyfriend, Nick Martin! The chaos is immediate, starting with BMs, lice, and the truly cursed Poop Tic Tac. Nick shares about  life as a touring musician turned domestic boyfriend, Katie flexes her perfume powers, Dayna explains her anti-Labubu agenda, and the group dives into HomeGoods shame, celebrity sightings, and embarrassing things that shouldn't be embarrassing. In need of something cute and cool for the summer? Get yourself or whoever's on your daddy list a tee, hoodie, or daddy hat from our store! Please support our show and show off your love for Disrespectfully by repping our official gear :) K Love ya bye! Thank you to our sponsors! Betterhelp: This episode is brought to you by BetterHelp. Give online therapy a try at https://betterhelp.com/disrespectfully and get on your way to being your best self Hero Bread: Hero Bread is offering 10% off your order. Go to https://hero.co and use code DISRESPECTFULLY10 at checkout ZipRecruiter: Try ZipRecruiter FOR FREE at https://ZipRecruiter.com/DISRESPECT Quince: Go to https://Quince.com/disrespectfully for free shipping on your order and 365-day returns Willie's Remedy: Order now at https://drinkwillies.com and use code DISRESPECTFULLY for 20% off of your first order + free shipping on orders over $95, and enjoy life in the high country Connect with the Coven! Facebook: https://www.facebook.com/groups/1930451457469874 Reddit: https://www.reddit.com/r/disrespectfullypod/ Listen to us on Apple: https://podcasts.apple.com/us/podcast/disrespectfully/id1516710301 Listen to us on Spotify: https://open.spotify.com/show/0J6DW1KeDX6SpoVEuQpl7z?si=c35995a56b8d4038             Follow us on Social! Disrespectfully Instagram: https://www.instagram.com/disrespectfullypod Disrespectfully Tiktok: https://www.tiktok.com/@disrespectfullypod Katie Maloney Instagram: https://www.instagram.com/musickillskate Nick Martin Instagram: https://www.instagram.com/nodirectioncasa Dayna Kathan Instagram: https://www.instagram.com/daynakathan Leah Glouberman Instagram: https://www.instagram.com/leahgsilberstein Allison Klemes Instagram: https://www.instagram.com/allisonklemes/ Buy our merch! https://disrespectfullypod.com/ Disrespectfully is an Envy Media Production.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Dan: my daughter 11 years old now has had for some time very large dense and hard bowel movements. our family doctor had her taking miralax at smaller doses but no solutions for long term. we have tried making sure she gets enough fiber and water but do not know what is causing this or where to start. i literally have to break up her BMs to flush the toilet . thanks for your help                                                                                                                                                                            Charlene: hello and thank you for all your help. my wife and i have been on a body transformation journey for about two years now. we have not reached our goals, our goal is overall health but are trying to build muscle and eventually lower our body fat percentages to a healthy number. we have been on a high protein diet about a gram per pound of body weight . i know this is not great for long term. how long is too long to be on this sort of diet and how should we best go about cycling our diet for best results. trying to get down to the 20 - 30 % body fat from 40 -50%. we also strength train regularly                                                                                                                                                                                               Dan: my teenage son has alot of acne. nothing seems to do any good for it and its much worse under his shirt sleeves. our doctor wanted him to take an antibiotic di something or other. we have tried a couple or topical treatments but nothing seems to work how do we get to the bottom of this?                                          Jean: I wake up too many days now with brain fog, extreme fatigue, no energy and headaches. Different parts of my body have discomfort. Thank you for answering my question.                                                                                                                          Sheena: Hi Dr. C! Hope you and your team are well. (This is the third time I've written in regarding this question). My liquid vitamin D says 1 drop equals 1000iu. . I was wondering if I can trust that? Because it seems soo little compared to a tablet. I end up consuming more drops then I need to, just in case. Thx in advance for answering!               Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3523 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!